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Energy Homeostasis
Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed tyrosine phosphatase implicated in
the central control of energy homeostasis via negative regulation of leptin signaling. Mice with central
nervous system (CNS)-specific PTP1B deficiency demonstrate clear metabolic improvements, including
decreased body weight and adiposity presumably due to enhanced leptin sensitivity. Interestingly,
compound PTP1B:leptin double mutants show attenuated weight gain compared to leptin single mutants,
suggesting that the metabolic effects of PTP1B deficiency may also involve non-leptin signaling
pathways. Indeed, insulin and other non-leptin cytokines, such as interleukin-6, have been implicated in
the CNS control of energy balance, and these pathways are also candidates of PTP1B regulation. Thus,
whether or not the metabolic effects of PTP1B deficiency are due exclusively to enhanced leptin signaling
remains unclear. This dissertation examines the role of central PTP1B in the control of leptin receptordependent energy homeostasis. A leptin receptor-expressing cell specific PTP1B-deficient (LepRb PTP1B
/ ) mouse model was generated and its metabolic phenotype was analyzed in comparison to wildtype
controls and to whole body PTP1B knockouts. Though subtle phenotypic differences between LepRbPTP1B-/- and PTP1B-/- mice exist, LepRb-PTP1B-/- mice demonstrate a majority of the phenotype
observed in whole body PTP1B knockouts, including decreased body weight and adiposity and improved
leptin sensitivity compared to wildtype controls. To further elucidate whether or not central PTP1B
regulates non-leptin signaling pathways, a compound hypothalamic PTP1B:LepRb double mutant
(Nkx2.1-PTP1B-/-:LepRb-/-) was generated and metabolically phenotyped in comparison to hypothalamic
leptin receptor (Nkx2.1-LepRb-/-) and PTP1B (Nkx2.1-PTP1B-/-) mutant mice. While Nkx2.1-PTP1B-/mice show decreased body weight and adiposity compared to wildtypes, both Nkx2.1-PTP1B-/-:LepRb /and Nkx2.1-LepRb-/- show a severe obese phenotype marked by similarly increased weight gain, total fat
mass, food intake, and glucose intolerance, indicating that the metabolic benefits of hypothalamic PTP1B
deficiency are dependent upon functional leptin receptor signaling. Finally, whether PTP1B can regulate
interleukin-6 signaling was explored using an immortalized mouse hypothalamic cell line. In summary,
these data show that PTP1B is a critical regulator of energy balance within leptin receptor-expressing
cells and within the hypothalamus specifically, and further begin to unravel the signaling pathways
mediating the beneficial metabolic effects of central PTP1B deficiency.
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ABSTRACT

THE ROLE OF PROTEIN TYROSINE PHOSPHATASE 1B IN THE CENTRAL REGULATION OF
ENERGY HOMEOSTASIS

Ryan C. Tsou
Kendra K. Bence

Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed tyrosine phosphatase
implicated in the central control of energy homeostasis via negative regulation of leptin signaling.
Mice with central nervous system (CNS)-specific PTP1B deficiency demonstrate clear metabolic
improvements, including decreased body weight and adiposity presumably due to enhanced
leptin sensitivity. Interestingly, compound PTP1B:leptin double mutants show attenuated weight
gain compared to leptin single mutants, suggesting that the metabolic effects of PTP1B deficiency
may also involve non-leptin signaling pathways. Indeed, insulin and other non-leptin cytokines,
such as interleukin-6, have been implicated in the CNS control of energy balance, and these
pathways are also candidates of PTP1B regulation. Thus, whether or not the metabolic effects of
PTP1B deficiency are due exclusively to enhanced leptin signaling remains unclear.

This

dissertation examines the role of central PTP1B in the control of leptin receptor-dependent
energy

homeostasis.

A

leptin

receptor-expressing

cell

specific

PTP1B-deficient

(LepRb-PTP1B-/-) mouse model was generated and its metabolic phenotype was analyzed in
comparison to wildtype controls and to whole body PTP1B knockouts. Though subtle phenotypic
differences between LepRb-PTP1B-/- and PTP1B-/- mice exist, LepRb-PTP1B-/- mice
demonstrate a majority of the phenotype observed in whole body PTP1B knockouts, including
decreased body weight and adiposity and improved leptin sensitivity compared to wildtype
controls.

To further elucidate whether or not central PTP1B regulates non-leptin signaling

pathways, a compound hypothalamic PTP1B:LepRb double mutant (Nkx2.1-PTP1B-/-:LepRb-/-)

v

was generated and metabolically phenotyped in comparison to hypothalamic leptin receptor
(Nkx2.1-LepRb-/-) and PTP1B (Nkx2.1-PTP1B-/-) mutant mice. While Nkx2.1-PTP1B-/- mice
show decreased body weight and adiposity compared to wildtypes, both Nkx2.1-PTP1B-/:LepRb-/- and Nkx2.1-LepRb-/- show a severe obese phenotype marked by similarly increased
weight gain, total fat mass, food intake, and glucose intolerance, indicating that the metabolic
benefits of hypothalamic PTP1B deficiency are dependent upon functional leptin receptor
signaling. Finally, whether PTP1B can regulate interleukin-6 signaling was explored using an
immortalized mouse hypothalamic cell line. In summary, these data show that PTP1B is a critical
regulator of energy balance within leptin receptor-expressing cells and within the hypothalamus
specifically, and further begin to unravel the signaling pathways mediating the beneficial
metabolic effects of central PTP1B deficiency.
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CHAPTER 1: Introduction

Obesity is a widespread and increasing health problem within the United States and
worldwide (Flegal et al., 2012; Popkin et al., 2012; Popkin and Slining, 2013). Based upon recent
estimates from the 2009-2010 National Health and Nutrition Examination Survey within the United
States, more than one third of the U.S. population is classified as obese (Body Mass Index,
BMI≥30), and approximately 70% of the total population is defined as overweight or obese
(BMI≥25) (Flegal et al., 2012). With its persistent rise in both youth and adult populations and its
associated comorbidities with type 2 diabetes, hypertension, and certain cancers (esophageal,
pancreatic, breast), obesity has enormous public health consequences (Ahima, 2006).
Furthermore, no effective, long-term treatment for obesity exists. Dieting and exercise are often
insufficient in maintaining sustained weight loss, whereas more invasive options such as bariatric
surgery are not cost-effective for treating the greater population (Stefater et al., 2012b). Thus,
understanding the underlying biological mechanisms which regulate body weight and adiposity is
of great importance and may lead to new insights for more effective treatment options.

Although obesity is predominantly thought to be a disease affecting the periphery (i.e.
increased fat mass deposition), the central nervous system (CNS) plays a key role in the
regulation of appetite, body weight, and metabolism. Neurons within the hypothalamus integrate
neuroendocrine signals from the periphery, detecting both short and long term energy status.
These neurons project to downstream hypothalamic and extrahypothalamic nuclei, and the
activity of these homeostatic circuits can elicit changes in feeding or energy expenditure,
ultimately leading to changes in body weight. Numerous cell signals play a role in the central
control of body weight, and disruption of cellular signaling pathways within the neurons underlying
energy balance can promote obesity.
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Phosphorylation is an important regulatory mechanism of these intracellular signaling
pathways;

the

opposing

actions

of

kinase

and

phosphorylation status of signaling components.

phosphatase

activity

determine

the

Indeed, metabolically relevant signaling

pathways such as leptin and insulin require several tyrosine phosphorylation events for
downstream signal transduction. While the action of protein tyrosine kinases (PTKs) initiating
signaling cascades is fairly well understood, relatively less is known regarding the role of protein
tyrosine phosphatases (PTPs) in these pathways.

PTPs can negatively regulate signaling

pathways by dephosphorylating phosphotyrosyl residues, but in some instances may actually act
as positive regulators of signaling. Gaining a better understanding of the role of CNS PTPs in the
control of energy balance is thus essential and may highlight PTPs as ideal therapeutic targets for
sensitizing signaling pathways disrupted in the obese state.

One such pathway is the

neuroendocrine leptin signaling pathway.

Leptin and the neuroendocrine control of body weight
Leptin is a 16 kDa protein secreted by adipose tissue and is found at circulating levels in
proportion to total body fat (Frederich et al., 1995). It was first discovered in 1994 through cloning
of the mouse ob gene (Zhang et al., 1994). Mice with mutations in leptin (ob/ob) are obese and
exhibit diabetic symptoms (Mayer et al., 1953; Garthwaite et al., 1980; Lindström, 2007).
Additional studies found that mice lacking leptin receptors (db/db or Lepr-/-) were similarly obese,
resulting from increased food intake and decreased energy expenditure (Friedman and Halaas,
1998). Like ob/ob mice, human leptin deficiency results in obesity (Montague et al., 1997), and
leptin replacement therapy has been shown to rescue the obese phenotype of genetic leptin
deficiency in both mice and humans (Farooqi et al., 1999). Exogenous intraperitoneal leptin
administration decreased food intake and body weight of both ob/ob and wild type mice, and
central intracerebroventricular administration also reproduced the food intake and body weight
reduction, suggesting leptin had direct effects within the brain (Campfield et al., 1995; Halaas et
al., 1995).
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Leptin acts through its receptor (LepR), encoded by the Lepr gene in the mouse.
Identified in 1995, the LepR belongs to the class I cytokine superfamily. At the time, only LepR
with a short intracellular domain was identified and cloned (LepRa). However LepRa was shown
to be closely related to the gp130 signaling-transducing component of the IL-6 receptor, the
leukemia inhibitory factor (LIF) receptor, and the granulocyte colony-stimulating factor (G-CSF)
receptor – all class I cytokine receptors containing long intracellular domains, suggesting the
possibility of alternatively spliced forms of the leptin receptor (Tartaglia et al., 1995). In fact, at
least six alternatively spliced isoforms of the LepR have since been identified in mice (Lee et al.,
1996; Margetic et al., 2002). The short form receptor, LepRa, is thought to play a role in transport
or uptake of circulating leptin. In contrast, the long form of the receptor, LepRb, contains a 320
amino acid cytoplasmic domain, capable of activating downstream intracellular signaling
cascades (Bjørbaek and Kahn, 2004; Leshan et al., 2006). Within the CNS, LepRb is expressed
in various regions of the brain. LepRb is expressed in a number of specific hypothalamic nuclei
including the arcuate nucleus, ventromedial hypothalamus, dorsomedial hypothalamus, lateral
hypothalamic area, and ventral premammillary nucleus (Mercer et al., 1996; Elmquist et al., 1998;
Scott et al., 2009; Patterson et al., 2011).

Additionally, LepRb is expressed in many

extrahypothalamic areas including the cortex, cerebellum, hippocampus, thalamus, nucleus
accumbens, ventral tegmental area, parabrachial nucleus, and hindbrain (Elmquist et al., 1998;
Scott et al., 2009; Patterson et al., 2011).

Despite broad central expression of the leptin receptor, the main effects of leptin on
energy homeostasis have focused on the hypothalamus. Indeed, the hypothalamus has the
highest number and concentration of leptin receptors (Patterson et al., 2011), and early rat lesion
studies implicated this brain region in the central control of energy balance (Brobeck et al., 1943;
Hetherington, 1944; Leibowitz et al., 1981). Within the arcuate nucleus, leptin acts upon two
subpopulations of neurons defined by which neuropeptides they express (Elias et al., 1998;
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Korner et al., 1999). The two groups of neurons express either the anorectic peptide precursor
pro-opiomelanocortin (POMC) or the orexigenic peptides neuropeptide Y (NPY) and Agoutirelated protein (AgRP). POMC is cleaved into alpha melanocyte-stimulating hormone (α-MSH),
and stimulation of POMC neurons by leptin increases expression of Pomc transcript, POMC
neuron excitability, and release of neurotransmitters, including α-MSH (Cowley et al., 2001). αMSH can then act on downstream melanocortin receptors inhibiting energy intake and increasing
energy expenditure (De Jonghe et al., 2011b). Conversely, leptin stimulation inhibits both AgRP
and NPY expression and hyperpolarizes AgRP/NPY neurons (Stephens et al., 1995; Glaum et
al., 1996; Schwartz et al., 1996; Elias et al., 1999). It is this dual action on two opposing neuron
populations that allows leptin to elicit its physiological effects of reducing food intake and body
weight. Leptin resistance is thought to underlie the obese disease state as obese individuals
have increased circulating leptin levels without the corresponding reductions in food intake or
body weight (Myers et al., 2008, 2010).

Leptin signaling is tyrosine phosphorylation dependent
At the cellular level, leptin binding to LepRb results in the activation of the associated
tyrosine kinase Janus kinase 2 (JAK2). JAK2 autophosphorylates and phosphorylates several
tyrosine residues along the intracellular tail of the LepRb including Y985, Y1077, and Y1138
(Bjørbaek et al., 1997; Li et al., 1999). Phosphorylation of Y985 allows for recruitment of tyrosine
phosphatase SHP2 and activation of extracellular signal-regulated kinase (ERK) 1/2 pathway,
while phosphorylation of Y1077 and Y1138 recruits the transcription factors signal transducer and
activator of transcription 5 and 3 (STAT5 and STAT3), respectively. Activated STAT5 or STAT3
can then translocate to the nucleus and regulate gene expression (White et al., 1997; Banks et
al., 2000) (Fig. 1.1). Thus, phosphorylation of Y985, Y1077, and Y1138 activates separate arms
of the leptin signaling pathway, each contributing to leptin’s metabolic effects in differing ways.
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Figure 1.1 Leptin signaling involves multiple tyrosine phosphorylation events. Leptin
binding results in activation and autophosphorylation of tyrosine kinase, JAK2. JAK2
can then phosphorylate the intracellular tail of LepRb including Y985, Y1077, and Y1138.

Through an elegant set of targeted substitution mutation studies, the metabolic
contribution of each specific tyrosine site was determined by the Myers Lab at the University of
Michigan. While Y985 phosphorylation leads to downstream ERK1/2, Y985 is also a binding site
for a negative regulator of leptin signaling, suppressor of cytokine signaling-3 (SOCS-3) (Bjorbak
et al., 2000). In mutant mice where Y985 is replaced with a leucine residue (l/l mice), normal
STAT3 signaling persists, and l/l mice show a lean metabolic phenotype due to loss of SOCS-3
inhibition of leptin signaling (Björnholm et al., 2007). Replacement of Y1077 with phenylalanine
residue (f/f mice) results in only a mild obese phenotype whereas serine substitution of Y1138
(s/s mice) results in a severe obese phenotype similar to db/db mice, suggesting that leptininduced JAK2/STAT3 signaling mediates the majority of leptin’s effects on energy balance (Bates
et al., 2003; Patterson et al., 2012). In addition to phosphorylation of LepRb tyrosine residues,
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JAK2 can phosphorylate insulin receptor substrate (IRS), allowing for downstream activation of
the phosphoinositide-3 kinase (PI3K)-Akt signaling pathway (Duan et al., 2004; reviewed in
Wauman and Tavernier, 2011).

Negative regulation of leptin signaling occurs via transcriptional feedback mechanisms as
well as through phosphatase activity. SOCS-3 is a leptin-inducible protein that acts as a negative
feedback inhibitor of leptin signaling via binding LepRb at Y985 (Fig. 1.1). Leptin injection in
ob/ob mice induces hypothalamic SOCS-3 mRNA whereas leptin injection in db/db mice shows
no effects (Bjørbaek et al., 1998). Furthermore, endogenous SOCS-3 expression is shown to be
regulated by the fed state in rats (Baskin et al., 2000). In addition to negative transcriptional
feedback, phosphatase activity reversing tyrosine phosphorylation plays a key role in leptin
signaling termination. Numerous PTPs (PTP1B, RPTPe, SHP2, TCPTP, and PTEN) have been
demonstrated to interact with the leptin signaling pathway, and increased PTP action has been
implicated as a possible cause for cellular leptin resistance (St-Pierre and Tremblay, 2012; Tsou
and Bence, 2012a). In diet-induced obesity mouse models, PTP1B and TCPTP expression are
increased in the hypothalamus, suggesting PTPs may contribute to the pathogenesis of obesity
(White et al., 2009; Loh et al., 2011).

Negative regulation of leptin signaling via phosphatase activity
The PTP superfamily consists of approximately 100 different PTPs, characterized by a
highly conserved active site motif (I/V)HCXXGXXR(S/T) with a conserved cysteine residue which
is essential for phosphate recognition and catalysis (Denu and Dixon, 1998; Tonks, 2003, 2006).
Structural diversity within domains attached to the core recognition motif defines a PTP’s
substrate specificity and cellular localization.

To date, five different PTPs have been

demonstrated to regulate leptin signaling, acting upon different substrates along the pathway, and
their roles in central control of metabolism have been studied through the use of genetic mouse
models (Table 1.1). These include receptor-type protein tyrosine phosphatase epsilon (RPTPe),
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Src homology 2 domain-containing protein tyrosine phosphatase (SHP2), T-cell protein tyrosine
phosphatase (TCPTP), phosphatase and tensin homolog deleted on chromosome 10 (PTEN),
and protein tyrosine phosphatase 1B (PTP1B) (St-Pierre and Tremblay, 2012).

RPTPe regulates leptin signaling via direct dephosphorylation of JAK2. Female RPTPedeficient mice demonstrate resistance to diet-induced obesity and increased energy expenditure
(Rousso-Noori et al., 2011).

Interestingly, leptin-induced JAK2 activation results in

phosphorylation of RPTPe on Y695 and enhances its ability to dephosphorylate JAK2, suggesting
that central leptin signaling can be regulated by a phosphorylation-dependent negative feedback
pathway (Rousso-Noori et al., 2011).

Early in vitro evidence suggested SHP2 could inhibit JAK2 activation or downregulate
STAT3-mediated gene transcription, therefore acting as a negative regulator of leptin signaling
(Carpenter et al., 1998; Li et al., 1999).

More recently however, SHP2 has been shown to

promote leptin signaling within the CNS, acting as an intermediate via binding Y985 of LepRb for
eliciting downstream ERK1/2 signaling. SHP2’s positive regulation of leptin signaling was further
demonstrated through the development of CNS SHP2-/- mouse models. Forebrain/neuronalspecific or pan-neuronal SHP2-/- mice show an obese phenotype with increased weight gain and
adiposity (Zhang et al., 2004; Krajewska et al., 2008). POMC neuron-specific deletion of SHP2
results in mice with increased body weight, adiposity, and serum leptin levels on both chow and
HFD; POMC-SHP2-/- mice also display impaired leptin sensitivity and peripheral glucose
homeostasis (Banno et al., 2010).

TCPTP negatively regulates leptin signaling via the direct dephosphorylation of STAT3.
In a comprehensive study by Loh et al., neuronal TCPTP-/- mice were generated and
metabolically phenotyped, providing in vivo evidence that TCPTP can regulate leptin-induced
JAK/STAT signaling. Neuronal TCPTP-/- mice are resistant to diet-induced obesity and display
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decreased adiposity and increased energy expenditure on HFD. Neuronal TCPTP-/- mice also
show enhanced leptin sensitivity (increased leptin-induced pSTAT3 levels in hypothalamus and
greater suppression of body weight/food intake) and peripheral glucose homeostasis as
measured by glucose and insulin tolerance tests. Furthermore, Loh et al. generated neuronal
PTP1B and TCPTP double knockouts; PTP1B-/-:TCPTP-/- mice are additively leaner and more
leptin hyper-sensitive than single PTP1B-/- mice when fed a HFD, demonstrating an example of
two PTPs acting on different substrates along the leptin pathway in vivo (Loh et al., 2011).

PTEN is a dual-specificity protein tyrosine phosphatase best known for its role as a tumor
suppressor (Li et al., 1997; Steck et al., 1997).

In spite of its role as a PTP, its primary

physiological target appears to be the phospholipid PIP3 rather than a tyrosine-phosphorylated
protein (Maehama and Dixon, 1998). Thus, PTEN negatively regulates leptin signaling at the
level of PI3K by directly dephosphorylating PIP3 into PIP2.

Interestingly, the metabolic

phenotypes of CNS PTEN mutant mouse models suggest a more complex role for PTEN in the
central regulation of energy balance. LepRb-specific deletion of PTEN results in decreased body
weight and adiposity, and oxygen consumption is increased compared to controls (Plum et al.,
2007). Surprisingly, LepRb-specific overexpression (OE) of PTEN in mice does not result in an
obese phenotype, and POMC- or ventromedial hypothalamus-specific PTEN deletion in mice
leads to counterintuitive increases in body weight (Plum et al., 2006; Klöckener et al., 2011;
Warne et al., 2011). Careful dissection of downstream PI3K pathways will be necessary in order
to further understand PTEN’s central metabolic role.

Perhaps the most well characterized PTP is PTP1B. PTP1B is a ubiquitously expressed
phosphatase encoded by the human gene PTPN1 (or Ptpn1 in mouse) (Tonks et al., 1988a,
1988b; Charbonneau et al., 1989; Brown-Shimer et al., 1990).

The human PTPN1 gene is

located on chromosome 20q13, a region which has been identified as a quantitative trait locus
associated with obesity and type 2 diabetes (Lembertas et al., 1997; Ghosh et al., 1999; Lee et
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al., 1999). More recently, a number of single nucleotide polymorphisms within the PTPN1 gene
associated with obesity and related metabolic disorders have been discovered in certain
populations (Di Paola et al., 2002; Echwald et al., 2002; Kipfer-Coudreau et al., 2004; Palmer et
al., 2004; Ukkola et al., 2005; Cheyssac et al., 2006; Meshkani et al., 2007; Bauer et al., 2010;
Mo et al., 2010; Tsou and Bence, 2012b). As described below, PTP1B has been shown through
both in vitro and in vivo studies to negatively regulate leptin and insulin signaling, functionally
demonstrating its role in the central regulation of energy balance and glucose homeostasis.

PTP1B and the metabolic effects of PTP1B deficiency
PTP1B was first isolated from human placenta as a 37kDa protein, but further isolation of
a cDNA clone for human PTP1B found the full length protein to be ~50kDa (Tonks et al., 1988a,
1988b; Brown-Shimer et al., 1990; Chernoff et al., 1990). It was the first PTP to be purified and to
have its crystal structure determined (Tonks et al., 1988a; Barford et al., 1994). The C-terminus
of PTP1B plays a role in its subcellular localization; the hydrophobic C-terminal 35 residues target
the enzyme to the cytoplasmic face of the endoplasmic reticulum (Frangioni et al., 1992).
Proteolytic cleavage by calpain of the C-terminus generates a soluble form of PTP1B with
increased activity (Frangioni et al., 1993). Early in vitro studies established PTP1B as an insulin
receptor phosphatase. Purified PTP1B was shown to antagonize insulin signaling when injected
into Xenopus oocytes. PTP1B injection increased endogenous levels of PTPase activity and
blocked insulin-stimulated tyrosine-phosphorylation (Cicirelli et al., 1990). Through the use of
site-directed mutagenesis, catalytically inactive “substrate-trapping” mutants were generated in
order to identify PTP1B targets (Flint et al., 1997). Substrate-trapping findings combined with
structural evidence led to the determination that PTP1B preferentially binds to the tandem
phospho-tyrosine motif (E/D)-pY-pY-(R/K), due to the presence of an additional phospho-tyrosine
recognition site adjacent to its catalytic site.

PTP1B was shown to preferentially bind and

dephosphorylate the insulin receptor (IR) at pY1162/pY1163 (Salmeen et al., 2000) and the
tyrosine kinases JAK2 and TYK2 at pY1007/pY1008 and pY1054/pY1055, respectively (Myers et
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al., 2001). Furthermore, PTP1B has been shown to dephosphorylate other receptor tyrosine
kinases including epidermal growth factor receptor (Flint et al., 1997), platelet-derived growth
factor receptor (Liu and Chernoff, 1997), and insulin-like growth factor receptor 1 (Kenner et al.,
1996). It is also likely that PTP1B can dephosphorylate tyrosine phosphorylated proteins such as
IRS-1 (Goldstein et al., 2000), Src (Bjorge et al., 2000), and p62Dok (Dubé et al., 2004).

PTP1B’s role in energy homeostasis was first revealed by the generation of PTP1Bdeficient mice.

By targeting deletion of exons 5 and 6 of the Ptpn1 gene, Elchebly et al.

generated global PTP1B-/- mice which were shown to be insulin hyper-sensitive and resistant to
high-fat diet induced obesity when compared to PTP1B+/+ animals.

PTP1B-/- mice show

enhanced and/or prolonged insulin-stimulated insulin receptor phosphorylation in liver and muscle
(Elchebly et al., 1999). A separate line of PTP1B-/- mice was generated by disrupting the ATGcoding exon 1 by Klaman et al in 2000. These mice were thoroughly metabolically phenotyped,
and consistent with the findings from Elchebly et al., this line of PTP1B-/- mice also showed
decreased body weight on HFD and improved peripheral glucose homoeostasis. Furthermore,
Klaman et al. determined that PTP1B-/- mice have increased energy expenditure, providing a
likely explanation for the lean metabolic phenotype. PTP1B-/- mice also demonstrate decreased
serum leptin levels, suggesting that they might be leptin hypersensitive (Klaman et al., 2000).
Indeed, PTP1B-deficiency was later shown to improve leptin sensitivity both in vitro and in vivo
(Zabolotny and Bence et al., 2002; Cheng et al., 2002). In 2002, Zabolotny and Bence et al. and
Cheng et al. found evidence that PTP1B negatively regulates leptin signaling. Zabolotny and
Bence et al. showed that leptin-induced phosphorylation of JAK2 and STAT3 is reduced in COS-7
cells coexpressing LepR and PTP1B when compared to cells expressing LepR alone (Zabolotny
et al., 2002). Both groups found increased leptin sensitivity in PTP1B-/- animals compared to WT
controls.

Using PTP1B substrate-trapping mutants, both groups determined that PTP1B’s

regulatory effects on leptin signaling occurs via direct dephosphorylation of JAK2 (Flint et al.,
1997; Cheng et al., 2002; Zabolotny et al., 2002).
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Through the use of conditional mouse genetics, a number of tissue-specific PTP1Bdeficient mouse models have been generated, providing insight into PTP1B’s central and
peripheral metabolic effects.

Brain-specific PTP1B-/- mice (generated with a nestin-cre

transgenic line) recapitulate the whole body PTP1B-/- phenotype and show improved body weight
and adiposity compared to controls on both chow and HFD; these mice display both decreased
food intake and increased energy expenditure, and are leptin and insulin hypersensitive (Bence et
al., 2006).

Interestingly, weight-matched female neuron-specific PTP1B-/- mice continue to

demonstrate improved insulin sensitivity compared to controls, suggesting that central PTP1B
deficiency may affect peripheral glucose homeostasis independent of body weight differences
(Bence et al., 2006).

Mice deficient in PTP1B specifically within POMC neurons

(POMC-PTP1B-/-) also show decreased body weight and adiposity, albeit only when fed a highfat diet, due to increased energy expenditure. Notably, on a chow diet POMC-PTP1B-/- mice
show improved glucose tolerance and insulin sensitivity even when controlled for body weight
and adiposity, confirming that central PTP1B can regulate peripheral glucose homeostasis
(Banno et al., 2010). POMC-PTP1B-/- mice also display enhanced leptin sensitivity within the
hindbrain and a heightened homeostatic response to cold exposure (De Jonghe et al., 2011a,
2012).

In contrast to CNS-PTP1B deficiency, peripheral PTP1B deletion does not yield a lean
body weight phenotype. Liver- and muscle-specific PTP1B deletion results in improvements in
peripheral glucose homeostasis and enhanced insulin sensitivity without effects on body weight
or adiposity (Bence et al., 2006; Delibegovic et al., 2007, 2009). Notably, liver-specific PTP1B-/mice also exhibit decreased markers of endoplasmic reticulum (ER) stress on a HFD (Delibegovic
et al., 2009; Agouni et al., 2011). The role of PTP1B in adipose is less clear; using the aP2driven Cre to generate PTP1B deficiency in fat tissue results in mice with increased body weight
on HFD.

However, whether adipocyte-specific PTP1B deletion explains the increased body

weight phenotype of aP2-PTP1B-/- mice is unclear. Only a ~50% reduction in PTP1B expression
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was observed in adipocytes isolated from WAT of aP2-PTP1B-/- mice, and aP2-Cre-mediated
recombination has been shown to occur in other cell types including macrophages, osteoblasts,
and cardiomyocytes (Bence et al., 2006; Mao et al., 2009; Wang et al., 2010). More recently,
adipocyte-specific PTP1B-/- mice were generated using the adiponectin-Cre line in order to
achieve a more efficient, adipocyte-specific deletion (Owen et al., 2012).

Adipocyte-specific

PTP1B deletion has no effect on body weight, glucose homeostasis, or total adiposity, but
increases adipocyte size, circulating glucose and leptin levels (Owen et al., 2012). Macrophagespecific PTP1B deletion has no effect on body weight but improves peripheral glucose and insulin
tolerance on HFD (Grant et al., 2013), suggesting the increased body weight observed in aP2PTP1B-/- mice is not attributed to adipocyte nor macrophage PTP1B loss. Taken together, the
findings from the tissue-specific PTP1B-/- models indicate that central PTP1B-deficiency
decreases body weight/adiposity and improves peripheral glucose homeostasis, while PTP1Bdeficiency in muscle or liver does not alter body weight but does significantly improve insulin
sensitivity and glucose tolerance.

Non-leptin signaling pathways implicated in the central control of energy homeostasis
Despite strong evidence that PTP1B centrally regulates energy balance via its interaction
with leptin signaling, whether or not the metabolic effects of PTP1B deficiency are exclusively due
to enhanced leptin signaling remains unknown. Indeed, there is evidence for PTP1B's leptin
independent metabolic effects.

In 2002, Cheng et al. found that leptin and PTP1B double

mutants (ob/ob;PTP1B-/-) show a leaner phenotype and increased resting metabolic rate
(normalized to body weight) than single leptin-deficient ob/ob mice, suggesting that in addition to
regulation of leptin signaling, PTP1B may also have leptin-independent effects important in
maintaining energy homeostasis (Cheng et al., 2002). Since ob/ob:PTP1B-/- mice continue to
express leptin receptors, the leaner phenotype of the double mutants compared to ob/ob single
mutants could also possibly be explained by ligand-independent activation and sensitized basal
activity of LepRb. Thus, whether or not PTP1B can regulate non-leptin pathways implicated in
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the CNS control of energy balance is unclear. Furthermore, other non-leptin signaling pathways
have been implicated in the central control of energy homeostasis including insulin and non-leptin
cytokines such as interleukin-6 (IL-6) or ciliary neurotrophic factor (CNTF), and there is evidence
that these signaling pathways are regulated by PTP1B as outlined below (Fig. 1.2).

Figure 1.2 PTP1B can regulate non-leptin pathways. In addition to regulation of leptin signaling,
PTP1B is a known regulator of insulin signaling and a potential regulator of non-leptin cytokine
signaling such as IL-6.
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Insulin is a pancreas-secreted hormone classically studied for its ability to stimulate
uptake of glucose and nutrients into peripheral target tissues. In the CNS however, insulin, like
leptin, has been shown to suppress body weight and food intake (Woods et al., 1979; Air et al.,
2002a) and affect neuropeptide gene expression and hypothalamic neuron activity (Schwartz et
al., 1992; Benoit et al., 2002; Choudhury et al., 2005). Similar to leptin signaling, insulin signaling
relies on phosphotyrosyl residues to elicit its downstream effects. In contrast to LepRb however,
the IR has intrinsic tyrosine kinase activity; upon ligand binding, the transmembrane β subunits of
the IR autophosphorylate on tyrosines Y1158, Y1162, and Y1163, recruiting downstream effector
proteins including IRS.

IRS becomes phosphorylated by IR on various Y residues and can

activate a number of downstream signaling pathways including the phosphoinositide-3 kinase
(PI3K)-Akt and MAPK pathways (reviewed in White, 1997). Historically, much of what is known
regarding the cellular mechanisms underlying insulin signaling has been studied within the
periphery, however, there are numerous studies supporting a connection between CNS insulin
signaling and energy homeostasis. Neuron-specific IR knockout (NIRKO) mice demonstrated
genetic evidence that central IR signaling plays an important role in regulating body weight
(Brüning et al., 2000). NIRKO mice displayed a mild obesity phenotype with increased body
weight and adiposity on HFD and mild insulin resistance as measured by insulin tolerance test
(Brüning et al., 2000). Furthermore, pharmacological studies have revealed that the reduction of
food intake by acute central insulin administration is PI3K-dependent (Niswender et al., 2003),
and in vitro models have identified the MAPK pathway as important for insulin’s ability to regulate
NPY/AgRP gene expression (Mayer and Belsham, 2009). PTP1B has been historically linked to
regulating insulin signaling in the periphery, and less is known regarding its interaction with
central insulin signaling. In 2008, Picardi et al. demonstrated that hypothalamic PTP1B can
regulate insulin signaling and insulin-induced food intake suppression.

Using anti-sense

oligonucleotides, Picardi et al. knocked down PTP1B expression within the hypothalamus of dietinduced obese rats and delivered insulin and measured food intake suppression.
hypothalamic

PTP1B

knockdown

demonstrated
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enhanced

insulin-induced

Rats with

food

intake

suppression. Insulin-induced IR or IRS phosphorylation was also enhanced in the hypothalamus
of rats with PTP1B knockdown (Picardi et al., 2008).

In addition to leptin, other cytokine signaling pathways have been shown to play a role in
the control of energy homeostasis.

Obesity is associated with a state of chronic low-level

inflammation as macrophage accumulation and increased levels of pro-inflammatory cytokines
are detected within adipose tissue (Wellen and Hotamisligil, 2005). IL-6 and CNTF are part of the
IL-6-type cytokine family, most studied for their role in inflammation and immune function. IL-6
mediates a variety of physiological functions including induction of acute phase proteins, cell
proliferation, survival, and apoptosis (Hodge et al., 2005). CNTF is also involved in numerous
cellular functions including cell survival, differentiation, and neuroprotection after acute injury
(Sleeman et al., 2000). Like leptin, IL-6-type cytokines signal through type I cytokine receptors.
Unlike leptin however, the receptors are complexes containing α and β subunits. The α-subunits
are non-signaling receptors which bind the cytokine ligand.

They complex with a dimer of

signaling β subunits that includes at least one copy of the transmembrane signal transduction
protein gp130Rβ (Febbraio, 2007). The gp130Rβ shares sequence homology with LepRb, and
both activate similar downstream signaling pathways such as JAK/STAT and ERK signaling
pathways (Ernst and Jenkins, 2004). IL-6 signals through a gp130Rβ homodimer whereas CNTF
signals through a heterodimer of gp130Rβ and LIFRβ receptors (Heinrich et al., 2003). When IL6 binds the IL-6Rα, gp130Rβ homodimerization occurs, allowing for signaling via activation of
associated tyrosine kinases JAK1, JAK2, and TYK2. CNTF can likewise activate gp130. The
gp130 associated janus kinases autophosphorylate and phosphorylate residues of the
cytoplasmic tail of gp130Rβ, allowing for binding of STAT transcription factors such as STAT3
and STAT1 (Heinrich et al., 1998).

Similar to transcriptional regulation of LepRb signaling,

STAT3-dependent transcription of SOCS provides negative regulation of IL-6-type receptor
signaling (Heinrich et al., 2003). Additional negative regulation of IL-6-type cytokine signaling
likely occurs via receptor endocytosis as well as JAK/STAT dephosphorylation, suggesting a
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possible role for PTP1B as a negative regulator of IL-6-type cytokine signaling (Castell et al.,
1988; Heinrich et al., 1998, 2003; Chang, 2011).

IL-6-type cytokines have been implicated in the central control of energy homeostasis. A
large proportion of circulating IL-6 is secreted from adipocytes and, like leptin, blood levels
correlate with adipose tissue mass (Mohamed-Ali et al., 1997; Bastard et al., 2000). Whether or
not circulating IL-6 can cross the blood brain barrier intact and affect the CNS is incompletely
understood (Banks et al., 1994). However, IL-6 has also been shown to be expressed within the
CNS in hypothalamic nuclei important for energy homeostasis (Schöbitz et al., 1993; Shizuya et
al., 1998). Wallenius et al. showed that mice lacking IL-6 develop mature-onset obesity. Mature
IL6-/- animals additionally showed increased circulating leptin levels and leptin resistance.
Interestingly, low dose IL-6 replacement reduced body weight and leptin levels in IL6-/- animals
(Wallenius et al., 2002b). The same group also went on to show that IL-6 delivered ICV in rats
can affect energy expenditure and body weight. Single ICV injection of IL-6 increased oxygen
consumption and carbon dioxide production in male rats, while chronic daily ICV injections
suppressed body weight and decreased total fat pad mass (Wallenius et al., 2002a, 2002b).

CNTF has also been shown to have central effects on body weight.

For example,

peripheral CNTF injections have weight reducing effects in ob/ob, diet-induced obese mice
resistant to leptin, and even in db/db mice (Gloaguen et al., 1997; Lambert et al., 2001).
Furthermore, CNTF administration can induce hypothalamic STAT3 phosphorylation (Lambert et
al., 2001). Direct central administration of CNTF reduces body weight and is blocked by the
orexigenic effects of NPY coinfusion (Pu et al., 2000). Interestingly, CNTF's food intake and
weight reducing effects do not appear to be localized to LepRb-expressing neurons, even though
CNTF signaling in POMC neurons appears to play a role (Janoschek et al., 2006; Stefater et al.,
2012a). Subcutaneous CNTF delivery also continues to have weight reducing effects in mice
with mediobasal hypothalamus lesions (Anderson et al., 2003).
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Though there is limited evidence implicating PTP1B in the regulation of IL-6-type cytokine
signaling, a few studies have linked PTP1B to IL-6. In smooth muscle cell cultures, IL-6 induced
JAK/STAT signaling is enhanced with PTP1B knockdown (Chang, 2011). Additionally, IL-6 has
been shown to downregulate hypothalamic PTP1B protein expression, improving central leptin
and insulin action (Chiarreotto-Ropelle et al., 2013). One study has examined CNTF signaling in
relation to PTP1B; in a human neuroblastoma cell line, CNTF treatment does not induce PTP1B
expression, nor does PTP1B overexpression affect CNTF-induced JAK2 and STAT3 activation
(Benomar et al., 2009). However, given that PTP1B's substrates include JAK2 and TYK2 (Myers
et al., 2001), two janus kinases associated with gp130 receptor signaling, PTP1B may be a
regulator of IL-6 and/or CNTF downstream gp130 activation.

Taken together, there is mounting evidence of potential PTP1B-regulated, non-leptin
signaling pathways which play a role in the central control of energy balance. We hypothesize
that PTP1B's contribution to the central regulation of energy homeostasis occurs via both leptindependent and -independent pathways. This dissertation examines the role of PTP1B in leptindependent and -independent pathways through a comprehensive metabolic study of novel
genetic mouse models as well as an in vitro signaling study.

To examine whether PTP1B can regulate non-leptin signaling pathways involved in the
CNS control of energy balance, we first began with an indirect approach, examining whether or
not LepRb-specific PTP1B deficiency demonstrates a partial or full recapitulation of whole body
PTP1B deficiency. As detailed in chapter 2, we generated LepRb-specific PTP1B-/- mice and
compared them to global PTP1B-/- mice in a battery of metabolic phenotyping measures. As
discussed in chapter 3, we next generated mice lacking both PTP1B and LepRb in the
hypothalamus (Nkx2.1-PTP1B-/-:LepRb-/- mice) and compared them to hypothalamus-targeted
LepRb-/- mice (Nkx2.1-LepRb-/- mice) to determine whether PTP1B deficiency can sensitize nonleptin pathways and improve the obese phenotype caused by genetic LepRb deletion in the
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hypothalamus. Chapter 4 details our use of an immortalized mouse hypothalamic cell line to
study the effects of PTP1B knockdown or overexpression on IL-6 induced JAK/STAT signaling.
Finally, in chapter 5 we discuss our findings within the context of the field and propose future
directions for additional study.
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PTP mouse model

Body Weight
and Adiposity
Phenotype

Leptin
sensitivity

Glucose
homeostasis

References

Global RPTPe-/- (whole
body)

↑ in females

↑ in females

Improved GTT
Improved ITT

Rousso-Noori et al.
2011

Forebrain-specific SHP2-/(CaMKIIα-Cre)

↑

↓

(Fed) Hyperglycemia
Hyperinsulinemia
Fatty liver

Zhang et al. 2004

Brain-specific SHP2-/(CRE3)

↑

↓

Impaired glucose
tolerance
Hyperinsulinemia

Krajewska et al.
2005

POMC-neuron specific
SHP2-/- (POMC-Cre)

↑

↓

Hyperinsulinemia
Impaired glucose
tolerance

Banno et al. 2010

Neuron-specific TCPTP-/(Nestin-Cre)

↓

↑

Improved GTT
Improved ITT

Loh et al. 2011

Neuron-specific TCPTP-/:PTP1B-/- (Nestin-Cre)

↓ (additive
effects)

↑ (additive
effects)

Improved ITT (additive
effects)

Loh et al. 2011

LepRb-specific PTEN-/(LepRb-Cre)

↓

Increased
leptin-induced
PI3K pathway

Improved GTT
Improved ITT
Decreased serum
insulin

Plum et al. 2007

LepRb-specific PTEN
overexpression (LepRbCre)

No change

Decreased
leptin-induced
PI3K pathway

Fatty liver

Warne et al. 2011

POMC-PTEN-/- (POMCCre)

↑, sex and dietdependent

Decreased food
intake
suppression

ND

Plum et al. 2006

VMH-specific PTEN-/(SF1-Cre)

↑

ND

ND

Klöckener et al.,
2011

Global PTP1B -/- (whole
body)

↓

↑

Improved GTT
Improved ITT

Klaman et al. 2000,
Echelby et al. 1999

Neuron-specific PTP1B -/(Nestin-Cre)

↓

↑

Improved GTT
Improved ITT

Bence et al. 2006

POMC-neuron specific
PTP1B -/- (POMC-Cre)

↓

↑

Improved GTT
Improved ITT

Banno et al. 2010

Table 1.1 Summary of CNS PTP-genetic mouse models and their associated metabolic
phenotypes. ↑, increased. ↓, decreased. ND, not determined.
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CHAPTER 2: Deficiency of PTP1B in LepRb-Expressing Neurons Leads to
Decreased Body Weight and Adiposity in Mice
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1

2

Department of Animal Biology, School of Veterinary Medicine; Department of Biobehavioral Health
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Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed tyrosine phosphatase
implicated in the negative regulation of leptin and insulin receptor signaling.

–/–

PTP1B

mice

possess a lean metabolic phenotype attributed at least partially to improved hypothalamic leptin
–/–

sensitivity. Interestingly, mice lacking both leptin and PTP1B (ob/ob:PTP1B ) have reduced
body weight compared to mice lacking leptin only, suggesting that PTP1B may have important
leptin-independent metabolic effects. We generated mice with PTP1B-deficiency specifically in
–/–

leptin receptor (LepRb) expressing neurons (LepRb-PTP1B ) and compared them to LepRb-Cre
only wild type controls (WT) and global PTP1B

–/–

mice.

Consistent with PTP1B’s role as a
–/–

negative regulator of leptin signaling, our results show that LepRb-PTP1B

mice are leptin

hypersensitive and have significantly reduced body weight when maintained on chow or high-fat
diet (HFD) compared to WT controls.

–/–

LepRb-PTP1B

mice have a significant decrease in

adiposity on HFD compared to controls. Notably, the extent of attenuated body weight gain on
–/–

HFD, as well as the extent of leptin hypersensitivity, is similar between LepRb-PTP1B
global PTP1B

–/–

mice.

mice and

Overall, these results demonstrate that PTP1B-deficiency in LepRb-

expressing neurons results in reduced body weight and adiposity compared to WT controls and
likely underlies the improved metabolic phenotype of global and brain-specific PTP1B-deficient
models.

–/–

Subtle phenotypic differences between LepRb-PTP1B
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and global PTP1B

–/–

mice,

however, suggest that PTP1B independent of leptin signaling may also contribute to energy
balance in mice.

Introduction
Obesity is a growing health problem in the United States and worldwide (Ahima, 2006; Flegal et
al., 2012). Numerous cellular signals play a role in body weight regulation including leptin. Leptin
is a 16 kDa hormone released by adipose tissue into circulation which plays a major regulatory
role in feeding and energy expenditure via action in the brain (Zhang et al., 1994). Circulating
leptin levels correlate with total body fat content, signaling to the central nervous system (CNS)
current levels of energy stores. Increasing levels of leptin signal a state of energy abundance to
the brain, suppressing food intake and increasing energy expenditure. Leptin-deficient ob/ob
mice are hyperphagic and develop obesity and insulin resistance (Pelleymounter et al., 1995).

The leptin receptor has multiple isoforms and only the “long form,” LepRb, is capable of
associating with the intracellular tyrosine kinase Janus kinase 2 (JAK2).

Leptin stimulation

activates JAK2 resulting in autophosphorylation and phosphorylation of several tyrosine residues
on LepRb allowing for recruitment and activation of downstream signaling molecules. LepRb has
broad central expression within the forebrain (hippocampus, hypothalamus, piriform cortex),
midbrain (dorsal raphe nuclei), and hindbrain (cerebellum, reticulotegmental nucleus, nucleus of
the solitary tract; NTS) (Elmquist et al., 1998; Leshan et al., 2006; Patterson et al., 2011). The
highest concentrations of LepRb-expressing neurons are found in hypothalamic nuclei including
the arcuate nucleus, ventromedial and dorsomedial nuclei of the hypothalamus, and the lateral
hypothalamus. Within the arcuate nucleus, two separate neuron populations expressing either
agouti-related protein (AgRP) or proopiomelanocortin (POMC) drive opposing effects on energy
balance. Leptin decreases food intake and increases energy expenditure by inhibiting orexigenic
AgRP neuron activity while stimulating anorexigenic POMC neurons. In the hindbrain, leptin
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induces pSTAT3 immunoreactivity in POMC NTS neurons and is also required for energy
balance regulation (Ellacott et al., 2006; Hayes et al., 2010).

Leptin signaling is regulated by multiple mechanisms including tyrosine phosphorylation. Protein
tyrosine phosphatase 1B (PTP1B) is an important negative regulator of leptin signaling through
the dephosphorylation of JAK2 (Cheng et al., 2002; Zabolotny et al., 2002).

PTP1B is a

ubiquitously expressed enzyme, however in the brain it shows enriched expression in areas of
high LepRb expression, including in the hypothalamus (Zabolotny et al., 2002). Consistent with
its role as a negative regulator of leptin signaling, global-, whole brain-, or POMC neuron-specific
deficiency of PTP1B in mice results in lean and leptin hyper-sensitive animals (Klaman et al.,
2000; Bence et al., 2006; Banno et al., 2010).

Muscle-, liver-, or adipocyte-specific PTP1B

deletion does not result in a reduction in body weight or adiposity, therefore PTP1B’s regulation of
body mass is likely to be centrally mediated (Bence et al., 2006; Delibegovic et al., 2007, 2009;
Owen et al., 2012). Global PTP1B knockout mice also show improvements in insulin sensitivity,
consistent with PTP1B being a known negative regulator of insulin receptor signaling (Ahmad et
al., 1995; Kenner et al., 1996). Indeed, deficiency of PTP1B in major insulin responsive tissues
(muscle or liver) results in enhanced insulin receptor signaling and improved glucose
homeostasis (Delibegovic et al., 2007, 2009). Interestingly, neuron-specific and POMC-neuron
specific PTP1B knockout mice also show improvements in peripheral insulin sensitivity even
when normalized for body weight and adiposity (Bence et al., 2006; Banno et al., 2010).

The lean metabolic phenotype of PTP1B-deficient mouse models is primarily attributed to
–/–

improved leptin sensitivity; thus, compound ob/ob:PTP1B

mice would be expected to exhibit a

similar metabolic phenotype compared to ob/ob single mutants, due to the complete loss of
–/–

circulating leptin. Intriguingly however, ob/ob:PTP1B

mice exhibit suppressed body weight gain

in comparison to ob/ob single mutants, suggesting that PTP1B’s metabolic effects may not be
solely due to its regulation of leptin signaling (Cheng et al., 2002). In a separate study, ob/ob
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mice treated with PTP1B anti-sense oligonucleotides showed decreased epididymal fat pad
weight when compared to saline treated mice (Zinker et al., 2002). Additionally, leptin receptor–/–

deficient PTP1B double mutants (db/db:PTP1B ) exhibit decreased plasma triglyceride and free
+/–

fatty acids compared to db/db:PTP1B

mice (Ali et al., 2009). Thus, the extent to which PTP1B

mediates its metabolic effects via central leptin-independent pathways remains unclear. Here, to
begin to address this, we generated mice with PTP1B-deficiency in leptin receptor-expressing
–/–

neurons (LepRb-PTP1B ) and examined body weight, adiposity, leptin sensitivity and glucose
–/–

homeostasis. LepRb-PTP1B

+/–

and LepRb-PTP1B

mice were compared to LepRb-Cre controls

as well as to whole-body PTP1B knockouts to examine whether PTP1B’s regulation of energy
homeostasis is limited to leptin receptor-expressing neurons.

Materials and Methods
Animal care. All animal care protocols and procedures were approved by the University of
Pennsylvania Institutional Care and Use Committee. We maintained mice on a 12-hour light/12hour dark cycle in a temperature- controlled barrier facility, with free access to water and food
(standard chow autoclavable Lab Diet 5010 or custom HFD Teklad TD93075). Age-matched
littermates were used for all experiments.

loxP/loxP

Mice with Lepr-specific deletion of PTP1B. Ptpn1

mice were generated previously and

genotyped by PCR as described (Bence et al., 2006). Genotyping primer sequences for the
Ptpn1 allele were: PTP1B forward 5′-TGCTCACTCACCCTGCTACAA, PTP1B reverse 5′loxP/loxP

GAAATGGCTCACTCCTACTGG; All Ptpn1

mice were originally on a mixed 129Sv/J ×

C57BL/6 background prior to mating with LepRb-Ires-Cre mice (gift from M. Meyers, University of
Michigan, Ann Arbor, Michigan), which were on a C57BL/6 background.
sequences for LepRb-Ires-Cre allele were:
Cre forward 5’-CCTCTCCACCCAAGCGGCCGGAGAACC
Cre reverse 5’-CCGGCTCCGTTCTTTGGTGGCCCCTTCGCG
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Genotyping primer

WT forward 5’-GCCCTCATTAATCTAGTAATGTAGATGG
WT reverse 5’-ACTAGGGGTCAACTCTC

Isolating DNA from tissues for detection of recombination of the floxed alleles. Tissues
were digested at 55°C overnight in proteinase K digestion buffer (100 mM Tris-HCl pH 8.5, 5 mM
EDTA, 0.2% SDS, 200 mM NaCl, 300 μg/ml proteinase K). Saturated NaCl (~6M) was added to
the digestion, and samples were vortexed vigorously for 1 minute. Samples were centrifuged for
20 minutes at 13,700 g, and supernatants were transferred to a fresh tube. DNA was precipitated
by adding 1 ml 100% ethanol, and pellets were washed once with 70% ethanol and were
resuspended in 100 μl of sterile PCR water for analysis.

PCR primers for detection of

recombined alleles were: Ptpn1∆/∆ forward 5′-GTGGTGCCTGCAAGAGAACTGAC
Ptpn1∆/∆ reverse 5′-GAAATGGCTCACTCCTACTGG
IL-2 internal control forward 5′-CTAGGCCACAGAATTGAAAGATCT
IL-2 internal control reverse 5′-GTAGGTGGAAATTCTAGCATCATCC

Body composition and food intake. At weaning, mice were placed on diets of either standard
laboratory chow (Lab Diet 5010; calories provided by protein [28.7%], fat [12.7%], and
carbohydrate [58.5%]) or custom HFD (Teklad TD93075; calories provided by protein [21.2%], fat
[54.8%], and carbohydrate [24%]). Body weights were assessed weekly for at least 18 weeks and
food intake was measured daily. Body length was measured as nose-rump length at indicated
age. Epididymal fat pads were dissected and weighed at indicated age.

Energy expenditure measurements. Adult male mice were transitioned from chow diet to HFD
at 9 weeks of age. Rectal temperature was measured with a thermistor during light cycle in
animals at 11 weeks of age (MicroTherma 2T; ThermoWorks). Brown adipose tissue UCP1 gene
expression was measured by qRT-PCR as described below.
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Leptin sensitivity. For in vivo leptin sensitivity measurements, recombinant mouse leptin 0.5
μg/g BW/injection (A.F. Parlow, NHPP) or an equal volume 0.9% saline was administered i.p. to
male mice on a chow diet (~7–8 weeks of age). Mice were initially injected with saline i.p. every
12 hours over the course of 36 hours.

After a recovery period of 24 hours, leptin was

administered morning and evening following the same paradigm. Body weight and food intake
were monitored daily for 4 days following the initial leptin injection. Baseline body weight and
food intake measurements for the days prior to the start of leptin injections were averaged and
used to calculate percent change. Animals acted as internal controls as each received both
saline and leptin injections using a within subjects design.

Glucose homeostasis. Glucose tolerance tests (GTTs) were performed as described previously
(Klaman et al., 2000). Glucose dose used for i.p. injections was 2 mg/g BW (20% solution).
Blood glucose was assayed in tail blood using a glucometer (Contour, Bayer). Fasting insulin
levels were determined as described below.

RNA extraction and real-time PCR. Mice were sacrificed at the onset of the light cycle (08:0010:00 a.m.) after overnight food withdrawal (fasted). Tissues were rapidly dissected and flash
frozen in liquid nitrogen. Total RNA was extracted from tissues using TRIzol (Invitrogen) and the
RNeasy kit (QIAGEN). cDNA was synthesized from 1 μg total RNA using the Advantage RT-forPCR kit (Clontech). The relative mRNA levels of UCP1, and Cidea were assessed and quantified
by quantitative real-time PCR (qRT-PCR). HPRT-1 (SABiosciences) was used as an internal
control. The qRT-PCR reactions were carried out using RT² SYBR Green qPCR Master Mix
(SABiosciences), and samples were run using the Eppendorf Mastercycler ep realplex. Primer
sequences for UCP1 and Cidea were reported previously (Seale et al., 2007). Relative mRNA
expression was calculated using the comparative Ct method as described previously (Bence et
al., 2006).
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Serum analysis. Trunk blood was collected from mice after overnight fast at indicated age.
Serum was separated by centrifugation at 6,000 g. Serum insulin and leptin were measured by
ELISA(CrystalChem).

Statistics. Results are expressed as mean ± SEM. Comparisons between groups were made
by unpaired 2-tailed Student’s t test or 2-way ANOVA with repeated measures in one factor
followed by Fisher’s protected least significant difference (PLSD) test, as appropriate. A p value
less than 0.05 was considered to be statistically significant.

Results
Generation of LepRb-specific PTP1B–/– mice.
To generate LepRb-specific PTP1B-deficient mice, we crossed Ptpn1

loxP/loxP

mice to LepRb

cre/cre

knock-in mice in which Cre recombinase is specifically expressed in LepRb-expressing-cells
(LepRb-Ires-Cre) (Leshan et al., 2006, 2009; Piper et al., 2008; Xu et al., 2012). The resulting
+/loxP

Ptpn1

cre/cre

LepRb

cre/cre

LepRb

LepRb

+/cre

mice were subsequently crossed to LepRb
+/loxP

mice.

Ptpn1

LepRb

cre/cre

loxP/loxP

–/–

+/–

+/+

cre/cre

LepRb

+/loxP

crossed Ptpn1

+/cre

LepRb

+/loxP

LepRb

cre/cre

(hereafter termed LepRb-

(LepRb-Cre) “wild type,” Cre-only littermate controls. In order

loxP/loxP

to increase numbers of Ptpn1

+/loxP

mice to yield Ptpn1

mice were crossed together to yield Ptpn1

(hereafter termed LepRb-PTP1B ), Ptpn1

PTP1B ), and Ptpn1

cre/cre

LepRb

cre/cre

and to generate all appropriate controls, we also

loxP/loxP

mice with Ptpn1

loxP/loxP

mice to yield Ptpn1

were then subsequently crossed together. This generated additional Ptpn1
–/–

loxP/loxP

(LepRb-PTP1B ) and Ptpn1
crossed PTP1B

+/–

LepRb

+/+

+/cre

LepRb

loxP/loxP

which
cre/cre

LepRb

(PTP1B fl/fl) controls. Finally, in a parallel cross we
–/–

mice together to generate whole-body PTP1B

and their respective PTP1B

+/+

“wild type” littermate controls.

To verify deletion of the PTP1B gene, we extracted DNA from a variety of tissues (hypothalamus,
brain without hypothalamus, pituitary, liver, hindlimb muscle, epididymal white adipose,

26

interscapular brown adipose, lung, heart, and kidney) and assessed for deletion of the floxed
–/–

allele via PCR. Deletion was only detected in hypothalamus tissue from LepRb-PTP1B

(Fig.

2.1). Although LepRb is also expressed outside of the hypothalamus (Elmquist et al., 1998;
Mercer et al., 1998; Leshan et al., 2006), no deletion was detected in whole brain without
–/–

hypothalamus or peripheral tissues of LepRb-PTP1B

mice, likely due to dilution of signal by

non-LepRb expressing cells and generally limited LepRb expression. No deletion was detected
in any tissues isolated from wild type control animals while deletion of the PTP1B gene was
detected in all tissues from whole-body PTP1B

LepRb-PTP1B

–/–

–/–

mice acting as positive controls.

mice have decreased body weight on chow and high-fat diet.

To assess whether energy balance is affected by PTP1B-deficiency in LepRb-expressing
neurons, we examined body weight in animals placed on normal chow or high-fat diet (HFD) at
–/–

weaning. Both LepRb-PTP1B

+/–

and LepRb-PTP1B

mice show significantly decreased body

weight on chow compared to Cre only wild type controls (Fig. 2.2A). No body weight differences
were found between PTP1B fl/fl “floxed” and LepRb-Cre only controls (data not shown).
contrast to LepRb-PTP1B

–/–

mice, global PTP1B

–/–

In

mice are similar in body weight compared to

their wild type littermate controls on chow diet as previously shown (Zabolotny et al., 2002) (Fig.
2.2B). When compared to whole-body PTP1B

–/–

mice, LepRb-specific PTP1B

–/–

on chow (Fig. 2.2C). On HFD, LepRb-PTP1B

–/–

mice weigh less

mice display a significant reduction in body

weight compared to wild type LepRb-Cre controls (Fig. 2.2D). Consistent with a previous report
+/–

for PTP1B

+/–

mice on HFD (13), LepRb-PTP1B

mice on HFD do not display decreased body

weight compared to wild type controls. Global PTP1B
–/–

to a comparable extent as that of LepRb-PTP1B

–/–

mice show reduced body weight on HFD

mice, demonstrating for the first time that the

protection against diet-induced obesity seen in PTP1B-deficient models is largely (if not
exclusively) due to PTP1B deficiency within LepRb-expressing neurons (Fig. 2.2E, 2.2F).
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LepRb-PTP1B

–/–

mice have decreased adiposity and body length on HFD.
–/–

In order to determine whether the decreased body weight of LepRb-PTP1B

mice reflects

decreases in fat mass or linear growth, we measured epididymal fat pad weights and body length.
–/–

LepRb-PTP1B

mice on chow diet show a non-significant trend towards decreased adiposity as

measured by epididymal fat pad weight when compared to Cre-only wild type mice (Cre vs.
–/–

LepRb-PTP1B
–/–

PTP1B

0.368 ± 0.083g vs. 0.278 ± 0.036g, p =.341) (Fig. 2.3A). In contrast, global

mice have decreased adiposity compared to controls despite similar body weight (Fig.
+ +

–/–

2.3B, PTP1B / vs. PTP1B ; 0.410 ± 0.059g vs. 0.193 ± 0.020g, p< 0.01). On HFD, adiposity is
–/–

+/–

significantly decreased in LepRb-PTP1B , LepRb-PTP1B , and global PTP1B

–/–

mice at 18

weeks of age compared to their respective controls (Fig. 2.3A, 2.3B).

–/–

Body length of LepRb-PTP1B

mice on chow is unchanged when compared to Cre-only wild

type controls (Fig. 2.3C). Likewise, whole-body PTP1B

–/–

mice show no difference in body length

compared to their respective controls on chow (Fig. 2.3D).
+/–

LepRb-PTP1B
(Fig. 2.3C).

–/–

On HFD, LepRb-PTP1B

and

mice display significantly decreased body length compared to Cre-only controls
–/–

Similarly, whole-body PTP1B

on HFD also show decreased linear growth

compared to controls (Fig. 2.3D).

Food intake and core temperature in LepRb-PTP1B

–/–

mice.
–/–

In order to determine the cause of the reduced body weight and adiposity in LepRb-PTP1B

mice, we measured daily food intake. Average daily food intake on both chow (Fig. 2.4A) and
–/–

HFD (data not shown) is slightly decreased in LepRb-PTP1B

compared to Cre-only wild types

although these differences do not reach statistical significance. To more carefully assess food
intake over time, cumulative chow food intake over the course of 1 week was measured.
–/–

Cumulative food intake is decreased in LepRb-PTP1B
–/–

2.4B). In contrast, global PTP1B

mice compared to controls on chow (Fig.

mice have increased average daily and cumulative food

intake on chow, consistent with past reports (Klaman et al., 2000) (Fig. 2.4C and 2.4D).
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–/–

Global, brain-specific, and POMC neuron-specific PTP1B

models exhibit a lean metabolic

phenotype and increased energy expenditure (Elchebly et al., 1999; Klaman et al., 2000; Bence
–/–

et al., 2006; Banno et al., 2010). To assess whether LepRb-PTP1B

mice showed enhanced

diet-induced adaptive thermogenesis, we measured core temperature after placing adult animals
–/–

(8 weeks of age) on a HFD for 2 weeks. Core temperature of LepRb-PTP1B

mice is elevated

by more than 0.5°C although this does not reach statistical significance (Fig. 2.4E, Cre vs.
–/–

LepRb-PTP1B ; 36.83 ± 0.39°C vs. 37.43 ± 0.16°C, p = .183). Since brown adipose tissue
(BAT) oxidizes chemical energy and is the central tissue promoting thermogenesis, we examined
expression of uncoupling protein 1 (UCP1) in BAT.
–/–

unchanged in LepRb-PTP1B

Interscapular BAT UCP1 expression is

mice compared to Cre-only controls (data not shown). Although

no differences were seen in BAT UCP1 expression, we measured expression of BAT gene
–/–

markers in epididymal white adipose to see if LepRb-PTP1B

mice showed increased

“browning” of white fat, which would indicate enhanced energy expenditure (Seale et al., 2007,
2011; Ishibashi and Seale, 2010; Petrovic et al., 2010). Interestingly, in chow fed animals the
brown fat markers, Cidea and UCP1, show a trend towards increased expression in the
–/–

epididymal white fat of LepRb-PTP1B

mice compared to Cre-only controls (Fig. 2.4F, All values

Cre vs. LepRb-PTP1B-/-; Cidea 1.098 ± 0.170 vs. 1.711 ± 0.339, p = .162; UCP1 1.108 ± 0.167
vs. 3.227 ± 1.335, p = .159).

LepRb-PTP1B

–/–

mice show enhanced leptin sensitivity.

Mice with whole-body, brain-specific, or POMC neuron-specific PTP1B-deficiency demonstrate
leptin hypersensitivity (Cheng et al., 2002; Zabolotny et al., 2002; Bence et al., 2006; Banno et
al., 2010). Given the leptin receptor expressing cell-specific deletion of PTP1B in this model, we
–/–

expected LepRb-PTP1B

mice to recapitulate this improvement in leptin sensitivity. No changes

in food intake or body weight were noted in any genotype in response to saline injection (Fig.
2.5A and 2.5B). In response to leptin treatment (0.5µg/g/injection, i.p.), food intake is suppressed
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–/–

–/–

to a similar extent in LepRb-PTP1B , PTP1B , and wild type controls (Fig. 2.5A and 2.5C).
–/–

However, LepRb-PTP1B

–/–

and PTP1B

mice show a significantly greater suppression of body

weight compared to their respective wild type controls (Fig. 2.5B and 2.5D), consistent with our
–/–

hypothesis that LepRb-PTP1B
body PTP1B

–/–

mice display a similar level of leptin hypersensitivity as whole-

mice. Additionally, we measured serum leptin levels from overnight fasted mice
–/–

on chow or HFD. On chow diet, serum leptin levels are unchanged in LepRb-PTP1B
compared to Cre-only wild types, while global PTP1B

–/–

mice

mice show decreased serum leptin

compared to PTP1B wild types, reflecting their reduced adiposity on chow (Fig. 2.5C). On HFD,
–/–

serum leptin levels are reduced in LepRb-PTP1B
–/–

global-PTP1B

mice compared to Cre-only wild types and in
–/–

compared to their respective controls (Fig. 2.5D Cre vs. LepRb-PTP1B ; 51.55

± 4.33ng/ml vs 24.87 ± 4.96ng/ml, p< 0.01, PTP1B

+/+

–/–

vs PTP1B ; 27.36 ± 3.56 vs 7.602 ± 1.71,

p< 0.01).

LepRb-PTP1B

–/–

mice show improvements in glucose homeostasis.

Since we previously found that neuronal deficiency of PTP1B can improve peripheral glucose
homeostasis (Bence et al., 2006; Banno et al., 2010), we examined glucose tolerance in LepRb–/–

PTP1B

–/–

mice compared to controls. On chow, LepRb-PTP1B

mice display similar glucose

clearance compared to Cre only controls as measured by a glucose tolerance test (GTT), and
have similar fasting serum insulin levels compared to controls (Fig. 2.6A and 2.6C). On HFD,
–/–

however, LepRb-PTP1B

show significantly improved glucose tolerance and fasting serum
–/–

insulin compared to Cre only controls (Fig. 2.6B and 2.6D, Cre vs. LepRb-PTP1B ; 2.076 ±
0.264ng/ml vs. 0.826 ± 0.087ng/ml, p< 0.01). As expected, global PTP1B

–/–

mice also show

significantly enhanced glucose clearance and lower fasting serum insulin levels compared to
controls (PTP1B

+/+

–/–

vs. PTP1B ; 1.987 ± 0.535ng/ml vs. 0.792 ± 0.135ng/ml, p< 0.01), and
–/–

displayed an additional enhancement in glucose clearance compared to LepRb-PTP1B

mice

most likely due to the additional deletion of PTP1B in muscle and liver (Elchebly et al., 1999;
Klaman et al., 2000; Delibegovic et al., 2007, 2009).
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Discussion
The extent to which PTP1B’s metabolic effects are mediated exclusively via LepRb-expressing
neurons was previously unknown. Our data clearly demonstrate an important role for PTP1B in
LepRb-expressing neurons in the control of body weight and leptin sensitivity in mice.
Additionally, our findings highlight subtle differences between PTP1B’s metabolic role in the
whole body compared to its restricted effects within leptin receptor expressing neurons,
suggesting an additional leptin-independent metabolic role for PTP1B.

Global PTP1B-deficiency, as well as neuronal PTP1B-deficiency, results in a lean metabolic
phenotype with decreased HFD-induced adiposity in mice (Klaman et al., 2000; Bence et al.,
–/–

2006). We demonstrate that LepRb-PTP1B

mice display a significant decrease in body weight

and adiposity when fed a HFD, which overall is indistinguishable from global PTP1B
–/–

Thus, the lean metabolic phenotype of global PTP1B

–/–

mice.

mice fed a HFD likely results from PTP1B

deficiency within LepRb-expressing neurons. Similar to mice with neuronal PTP1B-deficiency,
–/–

LepRb-PTP1B

mice fed a chow diet weighed less than wild type controls and global PTP1B
–/–

mice.

However, global PTP1B

–/–

mice do not show decreased body weight on chow diet.

Previous studies have found that muscle-, liver-, or adipocyte-specific deletion of PTP1B does not
result in decreased body weight or adiposity, while deletion of PTP1B in adipocytes and
macrophages using the aP2-driven cre results in weight gain (Bence et al., 2006; Delibegovic et
al., 2007, 2009; Owen et al., 2012). The lack of any body weight difference in chow-fed global
–/–

PTP1B

mice compared to controls may result from the combined effects of PTP1B deficiency in

both brain and macrophages; this interesting possibility remains to be explored. Interestingly,
global PTP1B

–/–

mice have reduced adiposity on chow diet despite similar body weight as wild
–/–

types, whereas LepRb-PTP1B

mice show a trend toward reduced adiposity on chow, despite

lower body weight.
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–/–

The decreased body weight and adiposity of LepRb-PTP1B

mice are potentially a combined

result of decreased food intake over time and increased energy expenditure due to enhanced
–/–

mice, and core

temperature and markers of white adipose “browning” tend to be higher.

Overall these

leptin sensitivity. Indeed, cumulative food intake is lower in LepRb-PTP1B

differences are subtle in magnitude, however this phenotype is consistent within the context of
other PTP1B-deficient models which show enhanced energy expenditure measured by indirect
calorimetry (Klaman et al., 2000; Bence et al., 2006; Banno et al., 2010), and is also consistent
with the fact that the reduction in body weight occurs slowly over time.

Previous models of PTP1B-deficiency have all demonstrated clear elevations in energy
expenditure (Klaman et al., 2000; Bence et al., 2006; Banno et al., 2010) whereas only brainspecific PTP1B

–/–

mice showed a decrease in food intake. Other neuronal populations which

express PTP1B (separate from LepRb- expressing-neurons) may also play a role in food intake
regulation, explaining the more pronounced suppression in food intake seen in complete brainspecific PTP1B knockouts. For example, insulin has been shown to have food intake reducing
effects (Woods et al., 1979; Schwartz et al., 1992; McGowan et al., 1993; Air et al., 2002b;
Carvalheira et al., 2003), and may act upon cell populations both overlapping and distinct from
LepRb-expressing populations. The insulin receptor (IR) is broadly expressed within the CNS
including the hypothalamus.

Moreover, PTP1B is a known regulator of insulin signaling via

dephosphorylation of IR and IRS (Seely et al., 1996; Bandyopadhyay et al., 1997; Byon et al.,
1998; Goldstein et al., 2000; Dadke and Chernoff, 2002). Although PTP1B deletion in LepRb
neurons may in turn sensitize insulin signaling pathways, the extent to which LepRb and IR are
coexpressed within the CNS is unclear, and in the case of POMC neurons, leptin and insulin
appear to signal in separate, distinct subpopulations (Williams et al., 2010).

–/–

Like global-, brain-, and POMC-PTP1B

–/–

mice, LepRb-PTP1B

also display improved glucose

tolerance and decreased circulating insulin levels on HFD.

Whether these indications of
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improved insulin sensitivity are independent of differences in body weight and adiposity is unclear
–/–

given LepRb-PTP1B

mice exhibit decreased body weight on chow and HFD.

There is
–/–

precedent for central PTP1B regulation of peripheral insulin sensitivity; POMC-PTP1B

mice

display improved insulin sensitivity even when controlled for body weight and adiposity. Given
the degree of overlap (at the neuronal level) in expression of POMC and LepRb, regulation of
peripheral insulin sensitivity by neuronal PTP1B may, at least partially, account for the
–/–

improvements seen in LepRb-PTP1B

mice. Central leptin signaling has been closely tied to the

control of peripheral glucose homeostasis (Morton, 2007; Li et al., 2011), and enhancing central
leptin sensitivity can improve insulin sensitivity at the periphery. Like PTP1B deficiency, deletion
of suppressor of cytokine signaling-3, a separate known negative regulator of leptin signaling,
results in improved peripheral glucose homeostasis (Mori et al., 2004; Kievit et al., 2006). Thus,
–/–

enhanced leptin sensitivity of LepRb-PTP1B

mice may underlie the improvements seen in

glucose tolerance and fasting insulin levels.

–/–

The subtle metabolic differences between LepRb-PTP1B

and global PTP1B

–/–

mice point

towards a distinct, metabolically significant role for PTP1B outside of leptin receptor expressing
neurons. The significant reduction in adiposity seen in chow-fed global PTP1B
–/–

LepRb-PTP1B

–/–

compared to

mice may be explained by PTP1B deficiency in non-LepRb expressing neurons

and/or in other tissues of global PTP1B

–/–

mice.

For example, PTP1B has been shown to

regulate BAT adipogenesis; preadipocyte cell lines derived from PTP1B

–/–

mice show enhanced

BAT differentiation when compared to wild type-derived cell lines (Miranda et al., 2010; Matsuo et
al., 2011). PTP1B deletion in whole body or brain results in increased activity of the fuel sensing
enzyme AMPK as well as increased UCP1 expression in BAT; increased AMPK activity in BAT
promotes expression of fatty acid oxidation and mitochondrial markers (Xue et al., 2009).
Additionally, non-leptin signaling pathways that play a role in the central control of energy
homeostasis may be sensitized in non-LepRb expressing neurons, potentially contributing to the
reduced adiposity phenotype limited to global PTP1B
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–/–

mice on chow. It should be noted that

–/–

although both LepRb-PTP1B

and global PTP1B

–/–

mice are on a mixed 129Sv/J × C57BL/6

background, the two lines were generated in parallel, and subtle differences in genetic strain may
also contribute to the metabolic differences observed.

In models of diet-induced obesity, whether leptin resistance is a cause or consequence of the
obese state is incompletely understood.

Current evidence support leptin resistance as a

consequence and subsequent facilitator of the obese state: HFD fed mice exhibit baseline
increases in arcuate pSTAT3 levels in absence of exogenous leptin (Björnholm et al., 2007).
Diet-induced obese animals tend to reduce food intake and body weight after removal of the
palatable diet, thus cellular leptin resistance is not enough to maintain the obese phenotype. In a
model of obesity proposed by Myers et al., increased caloric intake promotes weight gain,
increased adiposity, and cellular leptin resistance; the development of leptin resistance in turn
facilitates further weight gain (Myers et al., 2010).

This model suggests that cellular leptin

resistance develops over time, therefore the benefits of increased leptin sensitivity from LepRbspecific PTP1B deficiency would not be immediately noticeable in young animals. In spite of this,
global PTP1B

–/–

mice on HFD show body weight differences early on, near weaning age (Klaman

et al., 2000). Although these differences are small, our data was consistent with Klaman et al.
2000, with global PTP1B

–/–

mice displaying significant differences in body weight appearing as
–/–

early as 1-2 weeks post weaning (Fig. 2.2E). On the other hand, LepRb-PTP1B

mice display

decreased body weight on HFD at 7 weeks post weaning (10 weeks of age). This early weight
difference between global PTP1B

–/–

–/–

and LepRb-PTP1B

mice may be explained by PTP1B

outside of LepRb-expressing neurons sensitizing non-leptin signaling pathways which may affect
early growth and development. Alternatively, the temporal expression pattern of PTP1B within
–/–

LepRb-expressing neurons may be affecting early growth. For example, LepRb-PTP1B

mice

are capable of expressing PTP1B in LepRb-expressing progenitors until LepRb expression
occurs during development. LepRb expression in the brain occurs as early as embryonic day 14
(Matsuda et al., 1999), however global PTP1B

–/–
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mice lack PTP1B in all neurons throughout

development. Thus, the early loss of PTP1B in LepRb progenitors and/or non-LepRb neurons
may account for the small, early weight differences seen between global PTP1B
–/–

PTP1B

–/–

and LepRb-

mice.

Taken together, the data here suggest that PTP1B has both leptin-dependent and -independent
metabolic roles. Deletion of PTP1B in LepRb-expressing neurons clearly results in increased
leptin sensitivity and a lean metabolic phenotype, consistent with previous models of targeted
PTP1B-deficiency in vivo. While PTP1B deficiency in LepRb- expressing neurons encompasses
a majority of the metabolic phenotype in PTP1B-deficient models, differences between LepRb–/–

PTP1B

and global PTP1B

–/–

mice suggest PTP1B’s contribution to energy homeostasis

regulation also extends outside of leptin signaling.
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Figure 2.1 Detection of deletion of PTP1B floxed allele in LepRb-PTP1B-/- mice. DNA
was isolated from different tissues [hypothalamus (Hypo), brain without hypothalamus,
pituitary (Pit), liver, hindlimb, white adipose tissue (WAT), BAT, lung, heart, and kidney],
and deletion of floxed allele was detected by PCR.
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Figure 2.2 LepRb-PTP1B-/- mice have reduced body weight on chow and HFD.
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–/–

Figure 2.2 cont. (A) Body weights of male LepRb-PTP1B

(n=11), LepRb-PTP1B+/- (n=16),

and LepRb-Cre mice (n=9) on chow. (B) Body weights of male whole body PTP1B
–/–

and wild type controls (n=9) on chow. (C) Body weights of male LepRb-PTP1B
body PTP1B

–/–

mice on chow. (D) Body weights of male LepRb-PTP1B

–/–

–/–

(n=14)

and whole

(n=13), LepRb-

+/–

(n=23), and LepRb-Cre mice (n=16) on HFD. (E) Body weights of male whole body

–/–

(n=14) and wild type controls (n=13) on HFD. (F) Body weights of male LepRb-

–/–

and whole body PTP1B

PTP1B
PTP1B
PTP1B

–/–

mice on HFD. All values are mean±SEM. Weight curves

analyzed by 2-way ANOVA with repeated measures followed by pairwise comparisons:
#p<0.05 by 2-way ANOVA with repeated measures. *p<0.05 by Fisher’s LSD posthoc test for
indicated group compared to Cre (panels A, D) or wild type control (panel E). *p<0.05 by
Fisher’s LSD posthoc test for LepRb-PTP1B

–/–

compared to PTP1B
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–/–

mice (panel C).

–/–

Figure 2.3 LepRb-PTP1B

mice have decreased adiposity and body length on HFD.
–/–

(A) Epididymal fat pad weight of male LepRb-PTP1B

(n=10 chow, n=10 HFD), LepRb-

PTP1B+/- (n=16 chow, n=9 HFD), and LepRb-Cre mice (n=9 chow, n=8 HFD). (B) Epididymal
fat pad weight of male whole body PTP1B

–/–

mice (n=14 chow, n=14 HFD) and wild type
–/–

controls (n=9 chow, n=7 HFD). (C) Nose-rump length of male LepRb-PTP1B

(n=6 chow,

n=10 HFD), LepRb-PTP1B+/- (n=12 chow, n=9 HFD), and LepRb-Cre mice (n=6 chow, n=8
HFD). (D) Nose-rump length of male whole body PTP1B-/- mice (n=8 chow, n=14 HFD) and
wild type controls (n=13 chow, n=7 HFD). All values are mean±SEM. *p<0.05 for indicated
group compared to Cre or wild type control. **p<0.01 for indicated group compared to Cre
or wild type control.
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Figure 2.4 Food intake, core temperature, and expression of brown adipose tissue genes
–/–

in epididymal white adipose. (A) Average daily food intake of male LepRb-PTP1B

and
–/–

LepRb-Cre mice on chow (n=6/group). (B) Cumulative food intake of male LepRb-PTP1B
and LepRb-Cre mice on chow. (C) Average daily food intake of male whole body PTP1B

–/–

and wild type controls on chow (n=6/group). (D) Cumulative food intake of male whole
body PTP1B
–/–

PTP1B

–/–

and wild type controls on chow. (E) Core temperature of male LepRb-

and LepRb-Cre mice after 2 weeks of HFD (n=6/group). (F) Expression of Cidea
–/–

and Ucp1 in epididymal white adipose of male LepRb-PTP1B

and LepRb-Cre mice on

chow. All values are mean±SEM. *p<0.05 for indicated group compared to Cre or wild type
control. For cumulative food intake: *p<0.05 by 2-way ANOVA with repeated measures.
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–/–

Figure 2.5 LepRb-PTP1B

mice have increased leptin sensitivity. (A) Male mice (7 weeks

of age on a chow diet) were initially injected with saline i.p. every 12 hours over the course
of 36 hours indicated by the dashed bar. After 24 hours of recovery, mice were injected
with leptin (0.5 μg/g body weight every 12 hours for 48 hours) i.p. indicated by the solid bar
–/–

(n = 6/genotype). LepRb-PTP1B , whole body PTP1B

–/–

show suppression of food intake in response to leptin.
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mice, Cre and wild type controls

–/–

Figure 2.5 cont. (B) Male LepRb-PTP1B

and whole body PTP1B

–/–

mice show

suppression of body weight while Cre and wild type controls do not respond to low dose
leptin. (C) Percent change in food intake in response to leptin injection compared to saline
baseline. (D) Percent change in body weight in response to leptin injection compared to
saline baseline. (E) Fasting serum leptin levels in male LepRb-PTP1B
Cre mice (n=16), and whole body PTP1B

–/–

–/–

(n=17) and LepRb-

mice (n=14) and wild type controls (n=9) on
–/–

chow (18 weeks old). (F) Fasting serum leptin levels in male LepRb-PTP1B
LepRb-Cre mice (n=8), and whole body PTP1B

–/–

(n=7) and

mice (n=13) and wild type controls (n=7)

on HFD (18 weeks old). All values are mean±SEM. Leptin sensitivity analyzed by 2-way
ANOVA with repeated measures followed by pairwise comparisons: #p<0.05 by 2-way
–/–

ANOVA with repeated measures. *p<0.05 by Fisher’s LSD posthoc test for LepRb-PTP1B
compared to Cre control. ^p<0.05 by Fisher’s LSD posthoc test for PTP1B

–/–

vs. wild type

control. For serum leptin comparisons: *p<0.05 for indicated group compared to Cre or
wild type control. **p<0.01 for indicated group compared to Cre or wild type control.
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–/–

Figure 2.6 LepRb-PTP1B
–/–

male LepRb-PTP1B

mice on HFD have improved glucose tolerance. (A) GTT for

(n=10), and LepRb-Cre mice (n=7) on chow (8-10 weeks old). (B) GTT
–/–

for male LepRb-PTP1B

(n=8), LepRb-Cre (n=8), and whole body PTP1B

–/–

mice (n=6) on
–/–

HFD (8-10 weeks old). (C) Fasting serum insulin levels in male LepRb-PTP1B
LepRb-Cre mice (n=16), and whole body PTP1B

–/–

(n=17) and

mice (n=14) and wild type controls (n=9)
–/–

on chow (18 weeks old). (D) Fasting serum insulin levels in male LepRb-PTP1B
and LepRb-Cre mice (n=8), and whole body PTP1B

–/–

(n=10)

mice (n=14) and wild type controls

(n=7) on HFD (18 weeks old). All values are mean±SEM. GTT analyzed by 2-way ANOVA
with repeated measures followed by pairwise comparisons: #p<0.05 by 2-way ANOVA with
–/–

repeated measures. *p<0.05 by Fisher’s LSD posthoc test for LepRb-PTP1B
Cre control. ^p<0.05 by Fisher’s LSD posthoc test for PTP1B

–/–

compared to
–/–

vs. LepRb-PTP1B

mice.

For serum insulin comparisons: **p<0.01 for indicated group compared to Cre or wild type
control.
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CHAPTER 3: Improved Metabolic Phenotype of Hypothalamic PTP1B-Deficiency is
Dependent upon the Leptin Receptor
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This work was originally published in Molecular Metabolism 21 January 2014 (DOI:
10.1016/j.molmet.2014.01.008)

Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a known regulator of central metabolic signaling, and
mice with whole brain-, leptin receptor (LepRb) expressing cell-, or proopiomelanocortin neuronspecific PTP1B-deficiency are lean, leptin hypersensitive, and display improved glucose
homeostasis. However, whether the metabolic effects of central PTP1B-deficiency are due to
action within the hypothalamus remains unclear. Moreover, whether or not these effects are
exclusively due to enhanced leptin signaling is unknown.

Here we report that mice with

–/–

hypothalamic PTP1B-deficiency (Nkx2.1-PTP1B ) display decreased body weight and adiposity
on high-fat diet with no associated improvements in glucose tolerance. Consistent with previous
–/–

reports, we find that hypothalamic deletion of the LepRb in mice (Nkx2.1-LepRb ) results in
extreme hyperphagia and obesity. Interestingly, deletion of hypothalamic PTP1B and LepRb
–/–

–/–

–/–

(Nkx2.1-PTP1B :LepRb ) does not rescue the hyperphagia or obesity of Nkx2.1-LepRb

mice,

suggesting that hypothalamic PTP1B contributes to the central control of energy balance through
a leptin receptor-dependent pathway.
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Introduction
Obesity continues to be a major public health crisis in the United States and worldwide (Flegal et
al., 2012; Popkin et al., 2012; Popkin and Slining, 2013).

Given the numerous metabolic

comorbidities and an overall increased all-cause mortality associated with obesity (Catenacci et
al., 2009; Flegal et al., 2013), understanding the underlying biological systems that regulate body
weight and adiposity is of great importance. Though obesity is commonly thought of as a disease
affecting the periphery (i.e. increased body fat), the central nervous system (CNS) plays a key
role in regulating appetite, metabolism, and body weight.

Neurons within the hypothalamus

integrate neuroendocrine signals from the periphery, gauging short term and long term energy
status. The adipocyte-secreted hormone leptin is one such signal whose effects on the central
control of energy homeostasis have been studied in depth.

Circulating leptin acts on leptin

receptors (LepRbs) expressed within the hypothalamus and extrahypothalamic sites (hindbrain
nucleus tractus solitarius, parabrachial nucleus) (Scott et al., 2009; Patterson et al., 2011) to
suppress food intake and increase energy expenditure, ultimately promoting negative energy
balance. Leptin- (ob/ob) and LepRb-deficient (db/db) mice are hyperphagic and develop extreme
obesity (Zhang et al., 1994; Chua et al., 1996; Lee et al., 1996). Moreover, deletion of LepRb
within the hypothalamus in mice, driven by the ventral forebrain specific Nkx2.1-Cre, recapitulates
much of the db/db phenotype (Ring and Zeltser, 2010). LepRb-deficiency within the hindbrain
NTS in mice also results in hyperphagia and increased weight gain (Scott et al., 2011).

At the molecular level, when LepRb is activated, several tyrosine phosphorylation events occur.
Initially, leptin binding to LepRb results in a conformational change of the receptor and activation
of the associated tyrosine kinase Janus kinase 2 (JAK2).

JAK2 autophosphorylates and

subsequently phosphorylates tyrosine residues along the intracellular tail of LepRb, which can
further recruit downstream signaling molecules necessary for eliciting leptin’s physiological effects
(Bjørbaek and Kahn, 2004; Robertson et al., 2008). Protein tyrosine phosphatase 1B (PTP1B)
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shows enriched expression correlating with areas of LepRb expression (Zabolotny et al., 2002),
and is a known negative regulator of leptin signaling via direct dephosphorylation of JAK2 (Myers
et al., 2001; Cheng et al., 2002; Zabolotny et al., 2002). Whole body, whole brain-, LepRbexpressing cell-, or POMC neuron-specific PTP1B-deficiency results in decreased body weight
and adiposity on HFD (Elchebly et al., 1999; Klaman et al., 2000; Bence et al., 2006; Banno et al.,
2010; Tsou et al., 2012), whereas deletion of PTP1B in peripheral tissues does not affect body
weight (Delibegovic et al., 2007, 2009; Owen et al., 2012; Grant et al., 2013). Since CNS PTP1Bdeficient models to date have used holistic (whole brain) or neuron specific approaches (POMCor LepRb-targeted), the anatomic specificity of PTP1B’s metabolic effects remains unclear. Like
the LepRb, POMC is expressed both in the hypothalamus and hindbrain, and there is evidence of
–/–

enhanced hypothalamic and hindbrain leptin signaling in POMC-PTP1B

mice (Banno et al.,

2010; De Jonghe et al., 2012), suggesting a metabolic role for PTP1B in both regions. Thus, the
extent to which the metabolic effects of PTP1B deficiency are due to action within the
hypothalamus or in extrahypothalamic sites remains unknown. Here, to determine the metabolic
contribution of hypothalamic PTP1B, we generated a genetic PTP1B deficient mouse model
using the Nkx2.1-Cre line, which leads to widespread recombination within the ventral forebrain.

The improved metabolic phenotype of central PTP1B-deficient models is largely attributed to
enhanced leptin sensitivity.

Interestingly, however, compound ob/ob:PTP1B

–/–

mice show

attenuated weight gain in comparison to ob/ob mice (Cheng et al., 2002), suggesting that there
–/–

may be leptin-independent metabolic effects of PTP1B deficiency. Furthermore, db/db:PTP1B

mice display decreased plasma triglycerides and serum free fatty acids when compared to
+/–

db/db:PTP1B

(Ali et al., 2009), and ob/ob mice treated with PTP1B antisense oligonucleotides

possess decreased epididymal fat compared to saline-treated controls (Zinker et al., 2002).
Thus, we were interested in examining whether or not the metabolic effects of PTP1B deficiency
are exclusively leptin receptor dependent. For these studies, we crossed the Nkx2.1-Cre line with
loxP/loxP

Ptpn1

:Lepr

loxP/loxP

–/–

mice in order to generate compound hypothalamic Nkx2.1-PTP1B
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–/–

:LepRb

–/–

mice. Nkx2.1-PTP1B :LepRb

–/–

mice were compared to Nkx2.1-LepRb

–/–

mice as well

as wildtype controls to determine whether PTP1B's metabolic effects within the hypothalamus are
dependent upon functional leptin receptor signaling.

Materials and Methods
Animal care. All animal care protocols and procedures were approved by the University of
Pennsylvania Institutional Care and Use Committee. We maintained mice on a 12-hour light/12hour dark cycle in a temperature controlled barrier facility, with free access to water and food:
standard chow autoclavable Lab Diet 5010 (calories provided by protein [28.7%], fat [12.7%], and
carbohydrate [58.5%]) or custom HFD Teklad TD93075 (calories provided by protein [21.2%], fat
[54.8%], and carbohydrate [24%]). Age-matched littermates were used for all experiments.

–/–

–/–

–/–

Generation of Nkx2.1-PTP1B , Nkx2.1-LepRb , and Nkx2.1-PTP1B :LepRb
loxP/loxP

mice were on a C57BL/6 background. Ptpn1

–/–

mice. All

mice were generated previously (Bence et al.,

2006) on a mixed 129Sv/J × C57BL/6 background but were backcrossed at least 10 generations
onto C57BL/6 background prior to mating with other lines.

Lepr

loxP/loxP

mice on a C57BL/6

background were obtained from S. Chua (Albert Einstein College of Medicine) and S. Obici
(University of Cincinnati, Ohio). Nkx2.1-Cre transgenic mice were obtained from The Jackson
Laboratory (Stock #008661, Bar Harbor, ME). Genotyping primer sequences were as follows:
PTP1B fl forward 5′-TGCTCACTCACCCTGCTACAA
PTP1B fl reverse 5′-GAAATGGCTCACTCCTACTGG
Lepr fl forward 5′-AACGGTTTTACAGTCTCCA
Lepr fl reverse 5′-AAGGCCCATTTAGTCAAC
Nkx2.1-Cre forward 5′-CCACAGGCACCCCACAAAAATG
Nkx2.1-Cre reverse 5′-GCCTGGCGATCCCTGAACAT
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Isolating DNA from tissues for detection of recombination of the floxed alleles. Tissues
were digested at 55°C overnight in proteinase K digestion buffer (100 mM Tris-HCl pH 8.5, 5 mM
EDTA, 0.2% SDS, 200 mM NaCl, 300 μg/ml proteinase K). Saturated NaCl (~6M) was added to
the digestion, and samples were vortexed vigorously for 1 minute. Samples were centrifuged for
20 minutes at 13,700xg, and supernatants were transferred to a fresh tube.

DNA was

precipitated by adding 1 ml 100% ethanol, and pellets were washed once with 70% ethanol and
were resuspended in 100 μl of sterile PCR water for analysis. PCR primers for detection of
recombined alleles: Ptpn1∆/∆ forward 5′-GTGGTGCCTGCAAGAGAACTGAC
Ptpn1∆/∆ reverse 5′-GAAATGGCTCACTCCTACTGG
Lepr∆/∆ forward 5′-GTCTGATTTGATAGATGGTCTT
Lepr∆/∆ reverse 5′-ACAGGCTTGAGAACATGAACAC
IL-2 internal control forward 5′-CTAGGCCACAGAATTGAAAGATCT
IL-2 internal control reverse 5′-GTAGGTGGAAATTCTAGCATCATCC

Immunoblotting.

Mouse tissues were dissected and immediately frozen in liquid nitrogen.

Whole cell lysates were prepared in modified RIPA buffer containing fresh protease inhibitors,
and PTP1B and SHP2 immunoblotting was performed as described previously (Zabolotny et al.,
2002; Banno et al., 2010). PTP1B immunoblots were normalized to SHP2 (Santa Cruz
Biotechnology Inc., sc-280) to control for loading.

Body composition and food intake. At weaning, mice were placed on diets of either standard
laboratory chow or HFD. Body weights were assessed weekly and food intake was measured
daily at indicated age.

Body length was measured as nose-rump length at indicated age.

Epididymal fat pads were dissected and weighed at indicated age. Total fat and lean mass was
measured in conscious mice using NMR (Echo Medical Systems) at indicated age in the Penn
IDOM Mouse Phenotyping, Physiology and Metabolism Core.
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Energy expenditure measurements.

Rectal temperature was measured with a thermistor

during the light cycle in animals at 14-17 weeks of age (MicroTherma 2T; ThermoWorks). Feed
efficiency was calculated as grams weight gained/food consumed over indicated time period.
Brown adipose tissue gene expression (Ucp1 and Prdm16) was measured by real-time PCR as
described below.

Glucose homeostasis. Glucose tolerance tests (GTTs) were performed as described previously
(Klaman et al., 2000). Briefly, mice were fasted overnight (14-16 hours). Glucose dose used for
intraperitoneal injections was 2 mg/g BW (20% solution). Blood glucose was assayed in tail
blood using a glucometer (Contour, Bayer). Fasting insulin levels were determined as described
below.

RNA extraction and real-time PCR. Mice were euthanized at the onset of the light cycle (08:0010:00 a.m.). Tissues were rapidly dissected and flash frozen in liquid nitrogen. Total RNA was
extracted from tissues using TRIzol (Invitrogen) and the RNeasy kit (QIAGEN).

cDNA was

synthesized from 1 μg total RNA using the Advantage RT-for-PCR kit (Clontech). The relative
mRNA levels of Ucp1 and Prdm16 were assessed and quantified by quantitative real-time PCR
(qRT-PCR). The housekeeping gene hprt1 was used as an internal control. The qRT-PCR
reactions were carried out using RT² SYBR Green qPCR Master Mix (SABiosciences), and
samples were run using the Eppendorf Mastercycler ep realplex. Primer sequences for Ucp1 and
Prdm16 were reported previously (Seale et al., 2007). Relative mRNA expression was calculated
using the comparative Ct method as described previously (Bence et al., 2006).

Serum analysis. All blood samples were collected between 08:00 – 10:30am at indicated age.
Fasting blood samples were collected following overnight fast (14-16 hours).
separated by centrifugation at 6,000xg.

Serum was

Serum insulin and leptin (CrystalChem) and serum

corticosterone (Immunodiagnostic Systems) were measured by ELISA.
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Statistical analysis. Results are expressed as mean ± SEM. Comparisons between groups
were made by unpaired 2-tailed Student’s t test, 1-way ANOVA or 2-way ANOVA with repeated
measures in one factor followed by Fisher’s protected least significant difference (PLSD) or
Student-Newman-Keuls pairwise comparison, as appropriate.

A p value less than 0.05 was

considered to be statistically significant.

Results
Generation

of

mice with

hypothalamic-specific PTP1B deficiency or compound

PTP1B:LepRb deficiency.
In order to generate mice with PTP1B deficiency throughout the hypothalamus, we crossed
loxP/loxP

Ptpn1

mice to a line of transgenic Nkx2.1-Cre mice. The resulting Ptpn1

mice were subsequently crossed to Ptpn1

loxP/loxP

–/–

+/–

loxP/loxP

PTP1B ) mice, and Ptpn1

and Ptpn1

+/loxP

:Nkx2.1-Cre

loxP/loxP

mice to generate Ptpn1

+/loxP

(hereafter termed Nkx2.1-PTP1B ) mice, Ptpn1

+/loxP

:Nkx2.1-Cre

:Nkx2.1-Cre (hereafter termed Nkx2.1-

wildtype littermate controls. The Nkx2.1-Cre line

has been characterized previously (Ring and Zeltser, 2010), and strong Cre recombinase
expression is found broadly throughout the majority of the hypothalamus but is not detected in
caudal brain sites. In addition to the hypothalamus, Nkx2.1-Cre is known to be expressed within
the posterior pituitary, lung, thyroid, and the median ganglionic eminence, which may lead to
limited Cre expression within migrating cortical interneurons (Xu et al., 2008). Consistent with
–/–

past reports, Nkx2.1-PTP1B

mice indeed show decreased PTP1B protein expression in the

hypothalamus relative to wildtype controls, but do not show differences in total PTP1B protein
levels in lysates from extrahypothalamic brain (Fig. 3.1A).

To further explore whether the metabolic effects of CNS PTP1B deficiency are dependent upon
functional leptin signaling, we generated mice with compound conditional deletion of PTP1B and
loxP/loxP

LepRb in the hypothalamus. Ptpn1

mice were crossed to Lepr
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loxP/loxP

mice to generate

+/loxP

Ptpn1

:Lepr

loxP/loxP

Ptpn1

+/loxP

:Lepr

+/loxP

mice. Subsequently, Ptpn1

loxP/loxP

mice to yield Ptpn1

+/loxP

loxP/loxP

mice. Ptpn1
:Lepr

+/loxP

loxP/loxP

were crossed to Ptpn1

–/–

:Lepr

:Lepr

loxP/loxP

+/loxP

mice were intercrossed to generate

mice were then crossed with Nkx2.1-Cre
+/loxP

:Nkx2.1-Cre mice. Finally, Ptpn1

:Lepr

loxP/loxP

loxP/loxP

to yield Ptpn1

–/–

loxP/loxP

termed Nkx2.1-PTP1B :LepRb ) mice and Ptpn1
–/–

In a parallel cross, Nkx2.1-LepRb

–/–

detailed above for Nkx2.1-PTP1B

:Lepr

:Lepr

:Lepr

loxP/loxP

loxP/loxP

+/loxP

:Nkx2.1-Cre mice

:Nkx2.1-Cre (hereafter

littermate, wildtype controls.

mice were generated using the same breeding strategy

mice. To verify deletion of the Ptpn1 and Lepr genes, we

extracted DNA from a variety of tissues (hypothalamus, extrahypothalamic brain, pituitary, lung,
hindlimb muscle, epididymal white adipose, interscapular brown adipose, and liver) and assessed
for deletion of the floxed alleles by PCR. Deletion of the Ptpn1 and Lepr floxed alleles was only
detected in DNA extracted from hypothalamus, extrahypothalamic brain, pituitary, and lung (Fig.
–/–

3.1B) of Nkx2.1-PTP1B :LepRb

–/–

mice. No deletion was detected in DNA from any tissues

isolated from floxed wildtype control animals, and as expected only deletion of the Lepr floxed
–/–

allele was detected in Nkx2.1-LepRb

Nkx2.1-PTP1B

–/–

mice.

mice have decreased body weight on high-fat diet.
–/–

We examined weekly body weights of male and female Nkx2.1-PTP1B

mice and PTP1B fl/fl

controls on chow or high fat diet for at least 12 weeks from weaning. When fed a chow diet, male
and female Nkx2.1-PTP1B

–/–

+/–

and Nkx2.1-PTP1B

mice have similar body weights compared to
–/–

wildtype floxed controls (Fig. 3.2A and 3.2C). In contrast, HFD-fed male Nkx2.1-PTP1B
+/–

Nkx2.1-PTP1B

and

mice show significantly decreased body weight compared to wildtype controls
–/–

(Fig. 3.2B). Female Nkx2.1-PTP1B

+/–

and Nkx2.1-PTP1B

mice on HFD also display decreased

body weight compared to controls (Fig. 3.2D), but to a lesser extent than the males. Overall,
these data indicate hypothalamic PTP1B deficiency results in resistance to diet-induced obesity.
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Nkx2.1-PTP1B

–/–

mice have decreased adiposity on chow or HFD.

To determine whether differences in body weight reflect decreased fat mass or total body size,
body composition was assessed. Despite no difference in body weight on chow compared to
–/–

wildtype controls, male Nkx2.1-PTP1B

mice display significantly decreased adiposity as

determined by epididymal fat pad weight (Fig. 3.2E).

–/–

Male Nkx2.1-PTP1B

mice show no

difference in body length relative to controls on chow (Fig. 3.2F). Chow fed female Nkx2.1–/–

PTP1B

mice show no difference in either perigonadal fat pad weight or body length compared
–/–

to controls (Supplemental Fig. 3.1A and 3.1B). On HFD, male Nkx2.1-PTP1B

mice display

decreased adiposity as measured by epididymal fat pad weight as well as total fat mass by NMR
–/–

(Fig. 3.2E, 3.2G). Consistent with their reduced adiposity, male Nkx2.1-PTP1B

mice have

decreased circulating leptin levels compared to wildtypes (Table 3.1). On HFD, male Nkx2.1–/–

PTP1B

mice also show decreased lean mass and a concomitant decrease in body length (Fig.
–/–

3.2H and 3.2F). Female Nkx2.1-PTP1B

mice display decreased perigonadal fat pad weight

relative to wildtypes on HFD, but show no difference in body length (Supplemental Fig. 3.1C and
3.1D).

–/–

Nkx2.1-PTP1B :LepRb
Since past CNS PTP1B

–/–

–/–

mice exhibit obesity on chow or HFD.
models show a lean metabolic phenotype resulting presumably from

enhanced leptin sensitivity (Bence et al., 2006; Banno et al., 2010; De Jonghe et al., 2012; Tsou
et al., 2012), we examined the effects of compound Nkx2.1-PTP1B:LepRb deficiency on body
–/–

composition compared to Nkx2.1-LepRb

mice and wildtype controls to determine if functional

leptin receptor signaling is required for any metabolic contribution of PTP1B deficiency in the
hypothalamus.

–/–

Male Nkx2.1-LepRb

–/–

mice and Nkx2.1-PTP1B :LepRb

–/–

both display

significant weight gain compared to wildtype controls (Fig. 3.3A, chow diet and 3.3B, HFD).
–/–

Interestingly, male Nkx2.1-PTP1B :LepRb
–/–

Nkx2.1-LepRb

–/–

show no difference in body weight compared to

mice on chow or HFD, demonstrating that the metabolic effects of PTP1B

deficiency in the hypothalamus are in fact dependent upon functional leptin receptor signaling.
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–/–

Similarly, female Nkx2.1-LepRb

–/–

mice and Nkx2.1-PTP1B :LepRb

–/–

display significantly

increased body weight on chow or HFD relative to controls, and the extent of weight gain is
–/–

similar in Nkx2.1-LepRb

–/–

and Nkx2.1-PTP1B :LepRb

–/–

mice (Fig. 3.3C, chow diet and 3.3D,

HFD).

–/–

Nkx2.1-PTP1B :LepRb

–/–

mice display increased adiposity on chow or HFD.
–/–

–/–

and

–/–

–/–

and

We examined total fat mass, lean mass, and body length in Nkx2.1-PTP1B :LepRb
–/–

Nkx2.1-LepRb

–/–

Nkx2.1-LepRb

mice on chow or HFD.

On chow diet, male Nkx2.1-PTP1B :LepRb

mice display significantly increased total fat and lean mass compared to controls
–/–

as determined by NMR (Fig. 3.4A and 3.4B). Nkx2.1-PTP1B :LepRb

–/–

–/–

and Nkx2.1-LepRb

mice also show a nonsignificant trend toward increased body length when compared to wildtype
controls (Fig. 3.4C). Like body weight, the extent of increased fat mass, lean mass and length is
–/–

similar between Nkx2.1-PTP1B :LepRb

–/–

–/–

and Nkx2.1-LepRb

mice on chow. Total fat mass,
–/–

–/–

lean mass, and body length are also similar between Nkx2.1-PTP1B :LepRb
–/–

LepRb

–/–

:LepRb

and Nkx2.1–/–

mice on HFD (Fig. 3.4D, 3.4E and 3.4F). On chow or HFD, both Nkx2.1-PTP1B
and Nkx2.1-LepRb

–/–

mice display significantly elevated serum leptin levels consistent

with their increased adiposity (Table 3.1). Similar body composition and length measures are
–/–

also seen in female Nkx2.1-PTP1B :LepRb

–/–

and Nkx2.1-LepRb

–/–

mice with both groups

displaying significantly increased total fat and lean mass compared to wildtype controls on chow
or HFD (Supplemental Fig. 3.2 and data not shown), but no differences between the two groups.

Food intake, core temperature, and serum corticosterone measurements.
–/–

To examine the cause of the reduced body weight and adiposity observed in Nkx2.1-PTP1B

mice on HFD, we measured daily food intake and core temperature as a measure of
thermogenesis. Average daily food intake and cumulative food intake on HFD is reduced in male
–/–

Nkx2.1-PTP1B

compared to wildtype controls (Fig. 3.5A, 3.5B). Interestingly, feed efficiency
–/–

(Δbody weight/Δfood intake) and core temperature are similar in Nkx2.1-PTP1B
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and control

mice suggesting energy expenditure may not be affected in this model of hypothalamic PTP1B
deficiency (Fig. 3.5C and 3.5D). Consistent with this idea, core temperature is also comparable
–/–

when comparing Nkx2.1-PTP1B

and control mice at 17 weeks of age (Supplemental Fig. 3.3A).

Expression of Ucp1 in interscapular brown adipose tissue (BAT) and Prdm16, a gene which plays
a major role in brown fat determination, in inguinal white adipose tissue (WAT) were examined to
–/–

determine if BAT activation or WAT browning was enhanced in Nkx2.1-PTP1B

mice. Levels of
–

Ucp1 expression in BAT and Prdm16 expression in inguinal WAT were similar in Nkx2.1-PTP1B
/–

mice and wildtype controls (Supplemental Fig. 3.3B).

–/–

As expected from previous studies, Nkx2.1-LepRb

mice display significant hyperphagia as

demonstrated by increased average daily and cumulative food intake compared to wildtype
controls on chow (Fig. 3.5E and 3.5F). There were no differences in food intake across genders,
–/–

thus food intake data presented is from males and females combined. Notably, Nkx2.1-PTP1B
–/–

:LepRb

show similar levels of hyperphagia compared to Nkx2.1-LepRb
–/–

the food intake reduction seen in Nkx2.1-PTP1B

–/–

mice, suggesting that

mice is dependent upon functional leptin

receptor signaling. Feed efficiency (Fig. 3.5G, males and Supplemental Fig. 3.3C, females) is not
–/–

–/–

–/–

different between Nkx2.1-PTP1B :LepRb , Nkx2.1-LepRb , and wildtype control groups. Core
–/–

temperature is similar in all three male groups (Fig. 3.5H), but female Nkx2.1-PTP1B :LepRb
and Nkx2.1-LepRb

–/–

–/–

mice show significantly decreased core temperature relative to wildtype

controls (Supplemental Fig. 3.3D).

To assess whether hypothalamic PTP1B deficiency affects hypothalamus-pituitary-adrenal (HPA)
function, we measured morning serum corticosterone levels in ad lib fed male mice. Nkx2.1–/–

PTP1B

mice show similar serum corticosterone levels as wildtype controls on chow or HFD

(Table 3.1).

Leptin has been shown to play an important role in the regulation of the

hypothalamus-pituitary-adrenal (HPA) axis, and a previous report showed significantly elevated
–/–

serum corticosterone levels in Nkx2.1-LepRb

mice (Korner et al., 1999; Cohen et al., 2001;
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Ring and Zeltser, 2010). Consistent with these findings, we find elevated serum corticosterone in
–/–

Nkx2.1-LepRb

–/–

–/–

mice and also in Nkx2.1-PTP1B :LepRb

mice compared to wildtype controls

on chow (Table 3.1).

Nkx2.1-PTP1B

–/–

show minor improvements in fasting HFD-induced hyperinsulinemia.

Given that past CNS-specific PTP1B deficient models show improvements in peripheral glucose
tolerance and insulin sensitivity (Bence et al., 2006; Banno et al., 2010; Tsou et al., 2012), we
–/–

examined glucose homeostasis in Nkx2.1-PTP1B

compared to their respective controls.

Fasting blood glucose, serum insulin levels, and glucose tolerance are similar in male Nkx2.1–/–

PTP1B

+/–

and Nkx2.1-PTP1B

mice compared to wildtype controls on chow (Table 3.1, Figs.
–/–

3.6A, 3.6B). On HFD, fasting blood glucose is comparable in male Nkx2.1-PTP1B , Nkx2.1+/–

and wildtype mice, whereas fasting serum insulin is significantly decreased in Nkx2.1-

+/–

mice and trending toward a decrease in Nkx2.1-PTP1B

PTP1B
PTP1B

(Table 3.1).

–/–

mice compared to controls
–/–

Despite reduced serum insulin levels on HFD, however, Nkx2.1-PTP1B

and

wildtype controls perform similarly in an intraperitoneal GTT (Fig. 3.6C and 3.6D) and an ITT
(data not shown). Taken together, these results show that Nkx2.1-PTP1B deficiency results in
slight protection against HFD-induced hyperinsulinemia but no overt effects on overall glucose
homeostasis.

–/–

Nkx2.1-PTP1B :LepRb

–/–

mice show severe impairments in glucose homeostasis.

Hypothalamic deficiency of LepRb results in severely impaired glucose homeostasis marked by
elevated blood glucose and serum insulin levels and slower glucose clearance during a GTT
(Ring and Zeltser, 2010).
–/–

Although there are no differences in body weight or composition
–/–

between Nkx2.1-PTP1B :LepRb

–/–

and Nkx2.1-LepRb
–/–

–/–

additional PTP1B deficiency in Nkx2.1-PTP1B :LepRb

mice, we examined whether the

mice could have any beneficial effect
–/–

on glucose homeostasis independent of energy balance when compared to Nkx2.1-LepRb
–/–

mice. As expected, obese Nkx2.1-LepRb

mice show a trend toward increased fasted blood
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glucose levels on chow diet with a significant elevation in serum insulin levels (Table 3.1).
–/–

Surprisingly, Nkx2.1-PTP1B :LepRb

–/–

mice show no protection against hyperglycemia and

hyperinsulinemia, and if anything, have further impairments in these parameters compared to
–/–

Nkx2.1-LepRb
–/–

:LepRb

–/–

mice (Table 3.1). Glucose tolerance is severely impaired in Nkx2.1-PTP1B

and Nkx2.1-LepRb

–/–

mice on chow diet compared to wildtype controls, and the extent
–/–

of glucose intolerance is similar between Nkx2.1-PTP1B :LepRb
–/–

–/–

(Fig. 3.6E and 3.6F). On HFD, Nkx2.1-PTP1B :LepRb

–/–

–/–

and Nkx2.1-LepRb
–/–

and Nkx2.1-LepRb

mice

mice display

similarly elevated fasted blood glucose and increased fasting serum insulin compared to
wildtypes (Table 3.1).

Taken together, these data demonstrate that hypothalamus-targeted

PTP1B deficiency cannot rescue impaired peripheral glucose homeostasis in the context of
hypothalamic leptin receptor-deficiency.

Discussion
The anatomical specificity of PTP1B's metabolic contribution within the CNS is unclear since past
studies examined the effects of central PTP1B deficiency using holistic (all neurons) or cell-type
specific approaches (POMC-specific, LepRb-specific).

Furthermore, while central PTP1B

deficiency clearly enhances leptin sensitivity, whether or not the metabolic benefits from CNS
PTP1B-deficiency are solely the result of enhanced leptin signaling is unknown. Our data clearly
demonstrate an important role for hypothalamic PTP1B in the central control of energy
homeostasis in mice. Additionally, our findings clearly show that the metabolic improvements
observed with hypothalamic PTP1B deficiency are dependent upon functional leptin receptor
signaling.

Whole body, whole brain, LepRb-expressing cell or POMC-neuron specific PTP1B deficiency
results in decreased body weight and adiposity on HFD (Elchebly et al., 1999; Klaman et al.,
2000; Bence et al., 2006; Banno et al., 2010; Tsou et al., 2012). Consistent with past findings, we
demonstrate that hypothalamic PTP1B-deficiency reduces body weight and adiposity in mice on
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HFD. Somewhat surprisingly, the extent of the reduced body weight in hypothalamic PTP1B
knockouts is more modest compared to the whole body, whole brain, and LepRb-expressing cellspecific PTP1B-deficient models despite the hypothalamus being long regarded as the major
control center for energy balance.

While neuronal and LepRb-specific PTP1B

–/–

mice show

suppressed body weight gain even on a chow diet (Bence et al., 2006; Tsou et al., 2012), Nkx2.1–/–

PTP1B

mice do not show any body weight phenotype on chow, suggesting that genetic

deletion of PTP1B in the hypothalamus is not enough to confer reductions in body weight when
energy balance is not being pushed towards weight gain. Likewise, deleting PTP1B solely within
POMC neurons (representing a subpopulation of all LepRb-expressing neurons and a subset of
all hypothalamic neurons) also results in no effect on body weight on chow diet (Banno et al.,
2010).

Thus, the anatomic specificity of central PTP1B's total metabolic contribution clearly

includes the hypothalamus (Fig. 3.7), but also extrahypothalamic sites as the additional CNS
deletion in pan-neuronal and LepRb-expressing cell specific PTP1B

–/–

models results in

decreased body weights even on chow diet. Evidence of hindbrain PTP1B contribution has been
demonstrated using the POMC-specific PTP1B

–/–

model, whereby hindbrain (4th ventricle)

administration of leptin resulted in enhanced food intake and body weight suppression in POMC–/–

PTP1B

mice relative to wildtype controls (De Jonghe et al., 2012). Importantly, despite no
–/–

difference in body weight on chow, male Nkx2.1-PTP1B

mice show significantly decreased

epididymal fat, suggesting that hypothalamic PTP1B can regulate adiposity independent of body
–/–

weight. Although the decreased body weight of Nkx2.1-PTP1B
–/–

decreased fat mass, Nkx2.1-PTP1B

mice on HFD is primarily due to

mice also display a small decrease in lean mass and body

length. Indeed, past CNS PTP1B-deficient models have demonstrated small decreases in linear
growth, and there is evidence of PTP1B's regulation of melanocortin action (Banno et al., 2010;
De Jonghe et al., 2012; Tsou et al., 2012). In addition to the hypothalamus, the Nkx2.1 promoter
drives Cre expression in non-hypothalamic tissues including the pituitary and thyroid. Given that
these regions are implicated in neuroendocrine control of metabolism, it raises the possibility that
PTP1B-deficiency in these tissues may contribute to the observed metabolic phenotypes.
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However, our previous work has shown that pituitary-targeted Ptpn1 deletion does not result in
any metabolic phenotype (Banno et al., 2010), and thyroid function in whole body and POMC
neuron-specific PTP1B

–/–

mice is normal (Klaman et al., 2000; De Jonghe et al., 2011a),

suggesting that the metabolic effects reported here are in fact mediated through the
hypothalamus.

The improved metabolic phenotype of central PTP1B-deficient models have been explained by
increases in energy expenditure or a combination of suppressed food intake and increased
energy expenditure (Klaman et al., 2000; Bence et al., 2006; Banno et al., 2010; Tsou et al.,
–/–

2012). Like whole brain and LepRb-expressing cell specific PTP1B knockouts, Nkx2.1-PTP1B
mice demonstrate decreased food intake.

Thus, hypothalamic PTP1B deficiency likely

contributes to the decreased food intake seen in the neuronal and LepRb-PTP1B

–/–

mice; this is

consistent with the fact that decreasing hypothalamic PTP1B via 3rd ventricle antisense
oligonucleotide treatment results in significantly reduced food intake in rats (Picardi et al., 2008).
–/–

Interestingly, no changes in energy expenditure are detected in Nkx2.1-PTP1B

mice as

determined by feed efficiency, core temperature, or expression of BAT Ucp1, suggesting that the
energy expenditure effects of CNS PTP1B deficiency may be localized to extrahypothalamic
sites. One such site may be hindbrain LepRb/POMC-expressing neurons since both LepRb- and
POMC-specific PTP1B knockouts display increased energy expenditure (Banno et al., 2010;
–/–

Tsou et al., 2012). Indeed, hindbrain leptin administration in POMC-PTP1B

mice results in

greater increases in spontaneous activity and core temperature compared to wildtype controls
(De Jonghe et al., 2012). Alternatively, PTP1B might have competing opposing effects on energy
expenditure within different subpopulations of neurons in the hypothalamus; this possibility
remains to be explored.

In addition to affecting energy balance, central PTP1B has been implicated in the regulation of
peripheral glucose homeostasis (Bence et al., 2006; Banno et al., 2010; Tsou et al., 2012).
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Whereas whole brain, LepRb-expressing cell-, and POMC neuron-specific PTP1B

–/–

mice display

significant improvements in glucose tolerance, serum insulin levels, and insulin sensitivity,
hypothalamic PTP1B deficiency has no effect on glucose tolerance and only displays modest
effects on fasting insulin levels. Therefore, PTP1B deficiency in extrahypothalamic LepRb and
POMC neurons, likely in the hindbrain, may account for the improvements in glucose
homeostasis observed in other CNS-PTP1B deficient models.

Hypothalamic LepRb deletion in mice results in significantly increased weight gain and adiposity
similar to that seen in db/db mice (Ring and Zeltser, 2010). We demonstrate that compound
PTP1B and LepRb deficiency in the hypothalamus results in weight gain comparable to that of
–/–

Nkx2.1-LepRb

mice on both chow and HFD. Consistent with the results of Ring et al. 2010, we

also observed that female Nkx2.1-LepRb

–/–

–/–

and Nkx2.1-PTP1B :LepRb

–/–

mice had increased

body weight gain relative to males. In addition to body weight, body composition and length is
–/–

similar between Nkx2.1-PTP1B :LepRb

–/–

–/–

and Nkx2.1-LepRb

mice.

Both groups similarly

demonstrate significant hyperphagia and insulin resistance as demonstrated by elevated fasting
–/–

–/–

serum insulin and glucose intolerance. Interestingly, on chow, Nkx2.1-PTP1B :LepRb
display significantly elevated fasting insulin relative to Nkx2.1-LepRb

–/–

mice

mice, suggesting that

knocking out PTP1B on top of LepRb deficiency in the hypothalamus may intensify already
impaired glucose homeostasis.

However, whether or not a significant statistical difference

translates to a relevant physiological difference is unclear as both models demonstrate
impairments to glucose homeostasis several fold greater than wildtypes, and the same difference
was not observed on HFD. It has been demonstrated that ventromedial hypothalamus (VMH)specific insulin receptor deletion leads to protection from HFD-induced obesity and hyperglycemia
(Klöckener et al., 2011).

Therefore, one could speculate that within the context of LepRb-

deficiency, additional hypothalamic PTP1B deletion could sensitize VMH insulin signaling, leading
to further metabolic impairment. Specifically how hypothalamic PTP1B deletion could exacerbate
impaired glucose homeostasis within the context of LepRb deficiency remains unknown.
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Taken together, these findings indicate that hypothalamic PTP1B deficiency can elicit metabolic
improvements in body weight and adiposity within the context of diet-induced obesity where leptin
resistance accumulates over time. In contrast, under the conditions of genetic leptin resistance
where intracellular leptin signaling is completely impaired, PTP1B deficiency is ineffective at
improving metabolic outcomes, demonstrating that within the hypothalamus, functional leptin
receptor signaling is indeed required for PTP1B's metabolic effects. Based upon these findings,
we propose two possible models of central PTP1B action in the control of energy homeostasis:
(a) PTP1B's metabolic role in the CNS is exclusively as a negative regulator of leptin signaling,
and the metabolic benefit of PTP1B deficiency is solely the result of enhanced leptin sensitivity, or
(b) PTP1B acts on multiple signaling pathways (ex. insulin, non-leptin cytokines, growth factors
etc.) including leptin, and the metabolic effects of PTP1B deficiency are a combination of
numerous sensitized pathways of which leptin is the major contributor. Because PTP1B is a
known negative regulator of insulin signaling (Seely et al., 1996; Bandyopadhyay et al., 1997;
Byon et al., 1998) and JAK2 is associated with other non-leptin cytokine pathways implicated in
the central control of energy balance, it seems the latter possibility is more likely, but the
metabolic effects of these non-leptin pathways are masked by leptin’s larger contribution. For
example, though insulin and non-leptin cytokines including IL-6 and CNTF have been shown to
have weight-reducing effects when administered centrally (Woods et al., 1979; Schwartz et al.,
1992; McGowan et al., 1993; Sipols et al., 1995; Lambert et al., 2001; Wallenius et al., 2002a),
their physiological regulation of energy homeostasis seems much less considerable when
compared to leptin’s role.

Neuron-specific insulin receptor knockout mice only develop mild

obesity (Brüning et al., 2000), and global IL-6 knockout mice display an obese phenotype only
later in life (Wallenius et al., 2002b). In conjunction with our findings here, these studies further
suggest that the leptin contribution towards energy homeostasis regulation is far more substantial
than non-leptin pathways. Therefore, within the context of central PTP1B deficiency models,
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sensitized leptin signaling likely underlies the majority of the lean metabolic phenotypes
observed.

–/–

–/–

Alternatively, the lack of any phenotypic difference between Nkx2.1-PTP1B :LepRb
–/–

Nkx2.1-LepRb

and

mice could be attributed to loss of leptin signaling during early development

resulting in disrupted hypothalamic circuitry. Leptin has been demonstrated to act as a trophic
factor and is required during neonatal brain development for formation of projections from the
arcuate nucleus (Bouret and Simerly, 2004; Bouret et al., 2004).

Thus, perhaps disrupted
–/–

hypothalamic connectivity due to early loss of LepRb in Nkx2.1-PTP1B :LepRb

–/–

mice prevents

any non-leptin pathway sensitization to elicit measurable, beneficial metabolic effects. Future
studies utilizing inducible Cre lines may help to distinguish any confounding effects of early
hypothalamic development on energy balance function. All in all, these findings highlight the
continued importance of central leptin resistance as a main promoter of obesity.
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Figure 3.1 Detection of PTP1B deletion in Nkx2.1-PTP1B deficient mouse models.
–/–

(A) PTP1B protein levels in the hypothalamus and brain of Nkx2.1-PTP1B

(KO) mice

compared with PTP1B fl/fl controls (WT). SHP2 protein levels are shown as a loading
control. (B) Detection of deletion of PTP1B or LepRb floxed alleles in PTP1B fl/fl:LepRb
–/–

–/–

fl/fl, Nkx2.1-LepRb , and Nkx2.1-PTP1B :LepRb

–/–

mice. DNA was isolated from different

tissues [hypothalamus (Hypo), extrahypothalamic brain, pituitary (Pit), lung, hindlimb,
perigonadal white adipose tissue (WAT), brown adipose (BAT), and liver], and deletion of
floxed allele was detected by PCR.

62

–/–

Figure 3.2 Nkx2.1-PTP1B

mice have reduced body weight and adiposity on HFD.
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–/–

Figure 3.2 cont. (A) Body weights of male Nkx2.1-PTP1B

+/–

(n=9), Nkx2.1-PTP1B

(n=8),
–/–

and control PTP1B fl/fl (n=14) mice on chow. (B) Body weights of male Nkx2.1-PTP1B
+/–

(n=6), Nkx2.1-PTP1B

(n=6), and control PTP1B fl/fl (n=17) mice on HFD. (C) Body weights
–/–

of female Nkx2.1-PTP1B

+/–

(n=10), Nkx2.1-PTP1B

(n=8), and control PTP1B fl/fl (n=9) mice
–/–

on chow. (D) Body weights of female Nkx2.1-PTP1B

+/–

(n=15), Nkx2.1-PTP1B

(n=11), and

control PTP1B fl/fl (n=17) mice on HFD. (E) Epididymal fat pad weight for male Nkx2.1–/–

PTP1B

(n=9 on chow, 6 on HFD) and control PTP1B fl/fl (n=14 on chow, 9 on HFD) mice
–/–

on chow or HFD. (F) Body length for male Nkx2.1-PTP1B

(n=8 on chow, 6 on HFD) and

control PTP1B fl/fl (n=14 on chow, 9 on HFD) mice on chow or HFD. (G) Fat mass as
determined by NMR of male Nkx2.1-PTP1B

–/–

(n=6) and control PTP1B fl/fl (n=9) mice on

HFD. (H) Lean mass as determined by NMR of male Nkx2.1-PTP1B

–/–

(n=6) and control

PTP1B fl/fl (n=9) mice on HFD. All values are mean±SEM. Weight curves analyzed by twoway ANOVA with repeated measures: #p≤0.05. Fishers LSD post hoc pairwise
comparisons between Nkx2.1-PTP1B

–/–

and wildtype controls:*p<0.05. Body composition

and body length data analyzed by two tailed Student’s t-test: *p<0.05.
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–/–

Figure 3.3 Nkx2.1-PTP1B :LepRb
Nkx2.1-LepRb

–/–

–/–

mice show no difference in body weight compared to

mice.
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–/–

Figure 3.3 cont. (A) Body weights of male Nkx2.1-PTP1B :LepRb

–/–

(n=8), Nkx2.1-LepRb

–/–

(n=9), control PTP1B fl/fl:LepRb fl/fl (n=14) and control LepRb fl/fl (n=9) mice on chow. (B)
–/–

Body weights of male Nkx2.1-PTP1B :LepRb

–/–

(n=5), Nkx2.1-LepRb

–/–

(n=7), control

PTP1B fl/fl:LepRb fl/fl (n=11) and control LepRb fl/fl (n=7) mice on HFD. (C) Body weights
–/–

of female Nkx2.1-PTP1B :LepRb

–/–

(n=13), Nkx2.1-LepRb

–/–

(n=13), control PTP1B

fl/fl:LepRb fl/fl (n=15) and control LepRb fl/fl (n=15) mice on chow. (D) Body weights of
–/–

female Nkx2.1-PTP1B :LepRb

–/–

(n=6), Nkx2.1-LepRb

–/–

(n=13), control PTP1B fl/fl:LepRb

fl/fl (n=6) and control LepRb fl/fl (n=5) mice on HFD. All values are mean±SEM. Weight
curves analyzed by two-way ANOVA with repeated measures: *p<0.05.
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–/–

Figure 3.4 Male Nkx2.1-PTP1B :LepRb
compared to Nkx2.1-LepRb
–/–

Nkx2.1-PTP1B :LepRb

–/–

–/–

–/–

mice show no difference in body composition

mice. Fat mass (A) and lean mass (B) as determined by NMR of

(n=8), Nkx2.1-LepRb

–/–

(n=8), and control PTP1B fl/fl:LepRb fl/fl (n=3)
–/–

mice on chow. (C) Body length of Nkx2.1-PTP1B :LepRb
control PTP1B fl/fl:LepRb fl/fl (n=3) mice on chow.
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–/–

(n=8), Nkx2.1-LepRb

–/–

(n=8), and

–/–

Figure 3.4 cont. Fat mass (D) and lean mass (E) as determined by NMR of Nkx2.1-PTP1B
:LepRb

–/–

:LepRb

–/–

(n=5) and Nkx2.1-LepRb

–/–

(n=6) mice on HFD. (F) Body length of Nkx2.1-PTP1B

–/–

(n=5) and Nkx2.1-LepRb

–/–

(n=6) mice on HFD. Body composition and body length

on chow analyzed by one-way ANOVA followed by Student-Newman-Keuls pairwise
comparison: *p<0.05 indicated group vs control.
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–/–

Figure 3.5 Nkx2.1-PTP1B
–/–

PTP1B :LepRb

–/–

mice have decreased food intake on HFD whereas Nkx2.1-

mice show similar hyperphagia as Nkx2.1-LepRb
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–/–

mice.

–/–

Figure 3.5 cont. Average daily (A) and cumulative (B) food intake of male Nkx2.1-PTP1B
(n=5) and control PTP1B fl/fl (n=6) on HFD. (C) 7 day feed efficiency of male Nkx2.1–/–

(n=5) and control PTP1B fl/fl (n=6) on HFD. (D) Core temperature of male Nkx2.1-

–/–

(n=5) and control PTP1B fl/fl (n=14) on HFD at 8 weeks of age. Average daily (E)

PTP1B
PTP1B

–/–

and cumulative (F) food intake of male and female Nkx2.1-PTP1B :LepRb
LepRb

–/–

–/–

(n=9), Nkx2.1-

(n=6), and control PTP1B fl/fl:LepRb fl/fl (n=6) mice on chow. (G) 4 day feed
–/–

efficiency of male Nkx2.1-PTP1B :LepRb

–/–

(n=4), Nkx2.1-LepRb

–/–

(n=2), and control
–/–

PTP1B fl/fl:LepRb fl/fl (n=3) mice on chow. (H) Core temperature of male Nkx2.1-PTP1B
:LepRb

–/–

(n=4), Nkx2.1-LepRb

–/–

(n=2), control PTP1B fl/fl:LepRb fl/fl (n=8) mice on chow at

14 weeks of age. 24 hour food intake analyzed by two tailed Student’s t-test or one-way
ANOVA followed by Student-Newman-Keuls pairwise comparison: *p<0.05 indicated group
vs. control. Cumulative food intake analyzed by two-way ANOVA with repeated measures:
*p<0.05.
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Figure 3.6 Glucose tolerance is unchanged in Nkx2.1-PTP1B deficient models compared to
controls. (A) GTT for male Nkx2.1-PTP1B

–/–

(n=9) and control PTP1B fl/fl (n=8) mice on chow at

11 weeks of age. (B) Area under the curve (AUC) for blood glucose during GTT of male chow
–/–

cohort. (C) GTT for male Nkx2.1-PTP1B

(n=6) and control PTP1B fl/fl (n=9) mice on HFD at 17

weeks of age. (D) AUC for blood glucose during GTT of male HFD cohort. (E) GTT for female
–/–

PTP1B :LepRb

–/–

–/–

(n=5), Nkx2.1-LepRb

(n=7), and control PTP1B fl/fl:LepRb fl/fl (n=6) on chow

at 13 weeks of age. (F) AUC for blood glucose during GTT of female chow cohort. GTT analyzed
by two-way ANOVA with repeated measures: *p<0.05.
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Figure 3.7 Comparison of the anatomic specificity of various CNS PTP1B deficient mouse
models. LepRb and POMC are highly expressed in the arcuate nucleus (ARC) of the
hypothalamus and are also found in the nucleus of the solitary tract (NTS) of the medulla.
Outside of the NTS and hypothalamic nuclei including the ventromedial hypothalamic nucleus
(VMH), dorsomedial hypothalamic nucleus (DMH), lateral hypothalamic area (LHA), and ventral
premamillary nucleus (PMV), LepRb-expressing neurons are distributed broadly throughout the
brain, with known extrahypothalamic sites including the cortex, hippocampus (Hippo),
subfornical organ (SFO), ventral tegmental area (VTA), and the parabrachial nucleus (PBN).
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–/–

Supplemental Figure 3.1 Female Nkx2.1-PTP1B

mice have reduced adiposity on HFD.

–/–

(A) Epigonadal fat pad weight for Nkx2.1-PTP1B

(n=10) and control PTP1B fl/fl (n=8)

–/–

mice on chow. (B) Body length for Nkx2.1-PTP1B

(n=9) and control PTP1B fl/fl (n=8)
–/–

mice on chow. (C) Epigonadal fat pad weight for Nkx2.1-PTP1B

(n=9) and control

PTP1B fl/fl (n=13) mice on HFD. (D) Body length for Nkx2.1-PTP1B

–/–

(n=9) and control

PTP1B fl/fl (n=13) mice on HFD. Body composition and length data analyzed by two
tailed Student’s t-test: *p<0.05.
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–/–

Supplemental Figure 3.2 Female Nkx2.1-PTP1B :LepRb

–/–

mice show no difference in

body composition or body length compared to Nkx2.1-LepRb

–/–

mice on chow. Fat mass

–/–

(A) and lean mass (B) as determined by NMR of Nkx2.1-PTP1B :LepRb
LepRb

–/–

–/–

(n=9), Nkx2.1-

(n=7), and control PTP1B fl/fl:LepRb fl/fl (n=3) mice on chow. (C) Body length
–/–

for Nkx2.1-PTP1B :LepRb

–/–

–/–

(n=13), Nkx2.1-LepRb

(n=8), and control PTP1B fl/fl:LepRb

fl/fl (n=8) mice on chow. Body composition and body length analyzed by one-way
ANOVA followed by Student-Newman-Keuls pairwise comparison: *p<0.05 indicated
group vs. control.
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–/–

Supplemental Figure 3.3 Nkx2.1-PTP1B

mice show no difference in core temperature or brown
–/–

adipose tissue gene expression. (A) Core temperature of male Nkx2.1-PTP1B

(n=6) and

control PTP1B fl/fl (n=9) on HFD at 17 weeks of age. (B) Expression of Ucp1 and Prdm16 in
–/–

interscapular BAT and inguinal WAT, respectively of male mice Nkx2.1-PTP1B
–/–

control PTP1B fl/fl (n=9) on HFD. Female Nkx2.1-PTP1B :LepRb
feed efficiency or core temperature compared to Nkx2.1-LepRb
–/–

efficiency of female Nkx2.1-PTP1B :LepRb

–/–

–/–

–/–

(n=6) and

mice show no difference in

mice on chow. (C) Feed
–/–

(n=5), Nkx2.1-LepRb

(n=4), and control PTP1B
–/–

fl/fl:LepRb fl/fl (n=3) mice on chow. (D) Core temperature of female Nkx2.1-PTP1B :LepRb
(n=5), Nkx2.1-LepRb

–/–

(n=7), and control PTP1B fl/fl:LepRb fl/fl (n=6) mice on chow. Core

temperature analyzed by one-way ANOVA followed by Student-Newman-Keuls pairwise
comparison: *p<0.05 indicated group vs. control.
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–/–

0.35
±0.03

0.34
±0.02

Nkx2.1-PTP1B-/-:LepRb-/-

0.41
±0.03

Nkx2.1-LepRb-/-

73.8
±6.1

1B fl/fl:LepRb fl/fl

75.5
±7.5

Nkx2.1-PTP1B-/-:LepRb-/-

83.4
±5.8

Nkx2.1-LepRb-/-

nd

1B fl/fl:LepRb fl/fl

Nkx2.1-PTP1B-/-

Corticosterone
(ng/ml)

89.68
±20.25

Nkx2.1-PTP1B-/-

Nkx2.1-PTP1B+/-

1.20
±0.16

HFD

Nkx2.1-PTP1B+/-

1B fl/fl

1.14
±0.18

Chow

1B fl/fl

Genotype
Serum leptin
(ng/ml)

1.65
±0.21

Fasting blood
glucose
(mg/dl)

HFD

Fasting serum
insulin (ng/ml)

Chow

23.12
±4.61

6.69
±1.38*

11.50
±3.02*

8.18
±0.77

90.34
±4.79*

89.47
±5.88*

16.19
±4.91

104.68
±3.74*

127.88
±2.52*#

nd

82.89
±11.36

151.55
±29.95

407.29
±53.43*

361.75
±95.75*

nd

nd

nd

105.3
±9.8

92.0
±10.9

91.0
±10.2

62.3
±5.6

89.1
±18.4

107.6
±12.3*

94.3
±9.2

219.1
±29.3*

245.7
±78.2*

0.93
±0.17

0.37
±0.12*

0.55
±0.06^

0.48
±0.07

9.40
±1.47*

14.43
±2.76*#

0.62
±0.11

13.25
±4.37*

14.78
±9.60*

106.59 62.35
±28.96 ±24.53

Table 3.1 Metabolic and neuroendocrine parameters. Measures of fasting blood glucose
and fasting serum insulin are from overnight fasted male animals at 12-14 weeks of age
+/–

–/–

for controls, Nkx2.1-PTP1B , Nkx2.1-PTP1B

–/–

on chow or HFD. Fasting blood glucose
–/–

–/–

and fasting serum insulin of Nkx2.1-PTP1B :LepRb , Nkx2.1-LepRb , and control
PTP1B fl/fl:LepRb fl/fl mice are taken at 12-14 weeks on chow and at 9 weeks on HFD.
Measures of serum leptin and corticosterone are from ad lib fed male animals at 7 weeks
of age. Fasting blood glucose and serum measures analyzed by one-way ANOVA
followed by Fisher's LSD pairwise comparison: *p<0.05, ^p=0.08 indicated group vs.
–/–

control. #p<0.05 Nkx2.1-PTP1B :LepRb

–/–

–/–

vs. Nkx2.1-LepRb . nd, not determined.
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CHAPTER 4: IL-6 JAK/STAT Signaling is not regulated by Endogenous PTP1B in a
Hypothalamic Cell Line

Ryan C. Tsou and Kendra K. Bence
Department of Animal Biology, School of Veterinary Medicine; University of Pennsylvania, Philadelphia, PA.

Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed tyrosine phosphatase and
a known negative regulator of leptin signaling via the direct dephosphorylation of janus kinase 2
(JAK2). Interleukin-6 (IL-6) is an inflammatory cytokine which has been implicated in the central
control of energy balance, and like leptin, IL-6 signals through a type I cytokine receptor pathway
involving janus kinase activation. Using an immortalized, mouse embryonic hypothalamic cell line
(mHypoE-N46), we examined whether PTP1B can regulate IL-6 induced JAK/STAT signaling.
We determined that IL-6 dose-dependently induces STAT3 phosphorylation in mHypoE-N 46
cells, but does not detectably induce JAK2 or TYK2 phosphorylation. Knocking down
endogenous PTP1B using viral mediated shRNA does not enhance IL-6 induced STAT3
phosphorylation. On the other hand, PTP1B overexpression suppresses IL-6 induced STAT3
phosphorylation, suggesting PTP1B may regulate IL-6 signaling in a unidirectional and JAKindependent manner. Overall, these results suggest that endogenous PTP1B is likely not a key
regulator of hypothalamic IL-6 signaling. However, it remains possible that under conditions of
elevated hypothalamic PTP1B expression (as seen in high-fat diet and obesity), IL-6 activation of
STAT3 may be impaired.
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Introduction
Numerous cellular signaling pathways in the CNS (central nervous system) have been shown to
play a role in the control of body weight. Many of these pathways are regulated by tyrosine
phosphorylation, and protein tyrosine phosphatases have been implicated in the central
regulation of energy homeostasis. Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously
expressed tyrosine phosphatase and a known negative regulator of leptin signaling (Cheng et al.,
2002; Zabolotny et al., 2002). When leptin binds to its receptor, LepRb, a conformational change
results in activation of the associated tyrosine kinase janus kinase 2 (JAK2).

JAK2

autophosphorylates and phosphorylates several tyrosine residues along the cytoplasmic tail of
LepRb allowing for downstream signal transduction, including the recruitment of (signal
transducer and activator of transduction 3) STAT3, a transcription factor known to mediate
leptin’s effects on energy balance by regulating neuropeptide gene expression.

PTP1B

negatively regulates leptin signaling through the direct dephosphorylation of JAK2 (Myers et al.,
2001; Cheng et al., 2002; Zabolotny et al., 2002), and its role in the central control of energy
balance has been clearly demonstrated through the generation of PTP1B-deficient mouse
models. Whole body, whole brain, LepRb-expressing cell-, or POMC-specific PTP1B-/- mice are
resistant to diet-induced weight gain, likely due to enhanced leptin sensitivity (Elchebly et al.,
1999; Klaman et al., 2000; Bence et al., 2006; Banno et al., 2010; Tsou et al., 2012). However,
leptin deficient ob/ob:PTP1B-/- double mutants show attenuated weight gain compared to ob/ob
single mutants, suggesting that PTP1B may also regulate non-leptin pathways implicated in the
CNS control of energy balance (Cheng et al., 2002).

Interleukin-6 (IL-6) is a pro- or anti-

inflammatory cytokine, depending on cellular context, which has been shown to mediate a variety
of physiological functions including induction of acute phase proteins, cell proliferation, survival,
and apoptosis (Hodge et al., 2005; Ropelle et al., 2010).

Additionally, IL-6 has been

demonstrated to have central effects on energy balance, and obesity has been attributed with a
persistent, low dose inflammatory state (Dandona et al., 2004). IL-6-/- mice display mature onset
obesity which is ameliorated with IL-6 replacement therapy (Wallenius et al., 2002b).
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Furthermore, intracerebroventricular (ICV) but not intraperitoneal injection of IL-6 enhances
energy expenditure in rats, and chronic ICV delivery over two weeks reduces food intake, body
weight, and adiposity (Wallenius et al., 2002a, 2002b). Like leptin, IL-6 signals through type I
cytokine receptors. When IL-6 binds to its receptor complex, a conformational change in the
receptor complex leads to activation of an associated janus kinase: JAK1, JAK2, or TYK2. The
activated JAK autophosphorylates and phosphorylates the intracellular tail of gp130Rβ, the
transmembrane signaling subunit of the IL-6 receptor complex.

This allows for downstream

signal transduction and recruitment of STAT transcription factors such as STAT3 and STAT1
(Heinrich et al., 1998).

Given IL-6 signaling, like leptin, involves downstream tyrosine

phosphorylation events, phosphatase activity plays a role in negatively regulating IL-6-induced
signaling. Indeed, PTP1B has been demonstrated as a negative regulator of IL-6-stimulated
STAT3 phosphorylation in smooth muscle cells and hepatocytes (Chang, 2011; RevueltaCervantes et al., 2011). Importantly, whether or not PTP1B can regulate IL-6-induced JAK-STAT
signaling in the CNS is still unknown.

Here, we use an immortalized, mouse embryonic

hypothalamic cell line (mHypoE-N46) to examine whether PTP1B plays a role in IL-6-induced
JAK-STAT signaling.

Materials and Methods
Cell culture and reagents. mHypoE-N46 cells were grown in a monolayer and maintained in
DMEM plus 10% FBS and 1% penicillin/streptomycin at 37°C in a humidified atmosphere with 5%
CO2. Platinum-E (Plat-E) packaging cell lines were maintained in DMEM plus 10% FBS, 1%
penicillin/streptomycin, 1ug/ml puromycin and 10ug/ml blasticidin. Recombinant mouse IL-6 was
obtained from BioLegend (San Diego, CA). Recombinant mouse leptin was obtained from A.F.
Parlow, NHPP (Torrance, CA). Mouse PTP1B antibody was homemade (Klaman et al., 2000).
pSTAT3, pJAK2, and total JAK2 antibodies were purchased from Cell Signaling (Danvers, MA).
pTYK2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
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Viral mediated transduction of PTP1B shRNA or PTP1B overexpression vectors. PTP1B
knockdown was achieved using shRNA constructs designed against mouse PTP1B using the
pSUPER.retro.puro vector system (OlgoEngine). Human PTP1B overexpression was achieved
through the use of pWZL-hygro vector backbone. Knockdown or overexpression vectors were
transfected using PEI into Plat-E packaging cells.

48 hours later, viral supernatant was

harvested, filtered, and stored at -80°C. For PTP1B knockdown or overexpression, mHypoE-N46
cells were grown to 50% confluency and infected with retroviral supernatant. 24 hours later,
culture media was replaced with selection media (culture media plus puromycin 1.75ug/ml or
hygromycin 450ug/ml). Kill curves were completed to determine the dose for antibiotic selection.
Cells were maintained in selection media for 4-5 days prior to beginning of signaling studies.

Immunoblotting. mHypoE-N46 cells were serum starved overnight for 16 hours, and rinsed with
serum free media prior to stimulation with 1-20ng/ml IL-6. At indicated time points, cells were
harvested in modified RIPA buffer (10mM Tris pH 7.4, 150mM NaCl, 0.1% SDS, 1% Triton X-100,
1% Na deoxycholate, 5mM EDTA, 10mM Sodium Pyrophosphate, 10mM B-glycerophosphate,
50mM NaF) containing fresh protease (Protease inhibitor cocktail, Sigma) and phosphatase
inhibitors (1mM sodium ortho-vanadate) and 20-40ug of protein were resolved by SDS-PAGE
and transferred to PVDF membranes.

Immunoblots were performed with PTP1B, pSTAT3,

pJAK2, pTYK2, STAT3, and JAK2 antibodies.

Results
Leptin stimulation increases JAK2 and STAT3 phosphorylation in a hypothalamic cell line.
mHypoE-N46 cells were previously characterized and were found to be leptin responsive (Mayer
and Belsham, 2009; Dhillon and Belsham, 2011). Dhillon and Belsham found that 100nM leptin
significantly induced JAK2 phosphorylation but not STAT3 phosphorylation in mHypoE-N46 cells
serum starved for 4 hours. Here, we demonstrate that mHypoE-N46 cells respond to 100nM and
200nM leptin stimulation, inducing both JAK2 and STAT3 phosphorylation in mHypoE-N46 cells
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serum starved overnight (Fig. 4.1A). Relative pJAK2 and pSTAT3 levels were increased in leptintreated but not vehicle-treated mHypoE-N46 cells at 1 and 10 minute time points. These findings
suggest mHypoE-N46 cells are a suitable model for studying intracellular JAK/STAT signaling.

IL-6

stimulation

dose-dependently

increases

STAT3

but

not

JAK2

nor

TYK2

phosphorylation in mHypoE-N46 cells.
To first determine whether or not mHypoE-N46 cells respond to exogenous IL-6, we conducted a
dose-response signaling study. Serum starved mHypoE-N46 cells were treated with vehicle or 1,
5, 10, or 20 ng/ml IL-6 for 15 minutes, and relative levels of STAT3 phosphorylation were
determined by Western blot analysis.

IL-6 treatment dose-dependently induced STAT3

phosphorylation in mHypoE-N46 cells, whereas unstimulated or vehicle treated cells showed
relatively low levels of pSTAT3 expression (Fig. 4.1B).

Because the janus kinases JAK2 and TYK2 are known direct substrates of PTP1B and have
been implicated in mediating IL-6 signaling, we also looked at whether JAK2 or TYK2
phosphorylation was induced by IL-6 dose treatment. In contrast to leptin-treated cells, mHypoEN46 cells treated with IL-6 did not show any changes in pJAK2 levels compared to vehicle treated
cells. Additionally, levels of TYK2 phosphorylation were unchanged between vehicle and IL-6
treated cells, suggesting that JAK2 and TYK2 may not mediate intracellular IL-6-STAT3 signaling
in mHypoE-N46 cells (Fig. 4.1B).

IL-6 exposure does not affect PTP1B expression in mHypoE-N46 cells.
Central IL-6 administration has been shown to downregulate hypothalamic PTP1B protein levels
in vivo (Chiarreotto-Ropelle et al., 2013). Therefore, we looked at whether IL-6 exposure could
affect PTP1B expression levels in mHypoE-N46 cells.

Cells were incubated with vehicle or

5ng/ml IL-6 for 5, 30, 60, or 120 minutes, and PTP1B protein levels were measured by Western
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blot analysis. We observed no difference in PTP1B expression levels between mHypoE-N46
cells exposed to vehicle or IL-6 at any time point over the course of 120 minutes (Fig. 4.1C).

PTP1B knockdown does not enhance IL-6 induced STAT3 phosphorylation in mHypoE-N46
cells.
To determine whether IL-6 stimulated JAK-STAT signaling is regulated by endogenous PTP1B,
we knocked down (KD) PTP1B expression in mHypoE-N46 cells via retroviral delivery of a
PTP1B shRNA construct. Cells were transduced with virus expressing either scramble control or
PTP1B shRNA, followed by vehicle or IL-6 stimulation.

IL-6 (1ng/ml) induced STAT3

phosphorylation in both scramble and PTP1B KD cells at 5, 15 and 30 minutes to a similar extent;
STAT3 phosphorylation was not enhanced in PTP1B KD cultures (Fig. 4.2A).

PTP1B overexpression suppresses IL-6 induced STAT3 phosphorylation in mHypoE-N46
cells.
In addition to knocking down PTP1B expression, we examined the effects of PTP1B
overexpression on IL-6 stimulated JAK-STAT signaling. Interestingly, whereas PTP1B KD had
no effect on IL-6 induced STAT3 phosphorylation, overexpression of PTP1B suppressed IL-6induced STAT3 phosphorylation (Fig. 4.2B). In a separate experiment, we also looked at whether
JAK2 phosphorylation would be affected by human PTP1B overexpression in mHypoE-N46 cells.
JAK2 phosphorylation was unaffected by IL-6 stimulation (Fig. 4.2C).

Surprisingly, PTP1B

overexpression did not affect JAK2 phosphorylation, though IL-6-induced STAT3 phosphorylation
was suppressed (Fig. 4.2C).

Discussion
Whether or not PTP1B’s central metabolic effects are mediated exclusively through leptin
receptor signaling or through other pathways implicated in the CNS body weight control is
unknown. Because IL-6 has been shown to have CNS-specific weight reducing effects and its
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signaling pathway, like leptin’s, is subject to regulation by tyrosine phosphorylation, we examined
whether PTP1B could regulate hypothalamic IL-6 signaling in vitro. Our data demonstrate that IL6 dose-dependently induces STAT3, but not JAK2 or TYK2, phosphorylation in mHypoE-N46
cells and that endogenous PTP1B does not appear to be a key regulator of IL-6 JAK-STAT
signaling.

IL-6 has been shown to signal through the JAK-STAT signaling pathway (reviewed in Heinrich et
al., 1998). Past studies have demonstrated JAK1, JAK2, and TYK2 are all potential mediators of
IL-6-stimulated JAK-STAT signaling (Berger et al., 1994; Lütticken et al., 1994; Narazaki et al.,
1994). In mHypoE-N46 cells, IL-6 dose-dependently increased pSTAT3 levels but had no effect
on either JAK2 or TYK2 phosphorylation. JAK1 has been shown to be necessary for activation of
downstream STAT signaling whereas JAK2 and TYK2 were shown to be dispensable in human
fibrosarcoma cell lines (Guschin et al., 1995). Therefore, in mHypoE-N46 cells JAK1 may be
mediating STAT3 activation.

Alternatively, JAK-independent activation of STAT3 may be

occurring. In murine plasma B cells, IL-6 activation of STAT3 was shown to bypass all 3 janus
kinases, suggesting that IL-6 JAK/STAT signaling is different depending upon cellular context
(Kopantzev et al., 2002). Future studies are needed to address whether JAK1-mediated or JAKindependent activation of STAT3 occurs in this hypothalamic cell line, as well as in the
hypothalamus in vivo.

Central IL-6 administration has been shown to downregulate hypothalamic PTP1B protein
expression in obese rats after 6 hours (Chiarreotto-Ropelle et al., 2013). In myocytes, however,
PTP1B gene expression and activity is increased with 24 hour IL-6 treatment (Nieto-Vazquez et
al., 2008). We determined that IL-6 did not affect PTP1B expression in mHypoE-N46 cells after a
2 hour treatment. Further study with additional IL-6 doses and longer-term time points is required
to conclusively determine whether IL-6 treatment regulates PTP1B expression in mHypoE-N46
cells.
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IL-6-induced STAT3 activation has been demonstrated to be regulated by PTP1B in smooth
muscle cells and hepatocytes (Chang, 2011; Revuelta-Cervantes et al., 2011). Neither study
determined whether PTP1B regulated IL-6 JAK-STAT signaling via dephosphorylation of JAK2 or
TYK2 but showed clear effects of PTP1B expression on IL-6 induced pSTAT3 levels. Consistent
with the lack of IL-6 induced JAK2 and TYK2 phosphorylation, we show that PTP1B KD does not
enhance STAT3 phosphorylation in mHypoE-N46 cells, indicating that endogenous PTP1B may
not regulate IL-6 induced STAT3 phosphorylation. In PTP1B deficient macrophages isolated
from myeloid-cell-specific PTP1B-/- mice, IL-6 induced STAT3 phosphorylation was not elevated
(Grant et al., 2013), suggesting that PTP1B differentially regulates IL-6 signaling in different cell
types. Alternatively, although PTP1B levels were significantly decreased by shRNA knockdown,
the residual PTP1B activity may be sufficient to regulate IL-6 signaling in these cells.

Despite PTP1B KD having no effect on IL-6-induced STAT3 activation, overexpression of human
PTP1B results in a complete suppression of IL-6-induced STAT3 phosphorylation; JAK2
phosphorylation remains unaffected by IL-6 treatment and also is unaffected by PTP1B
overexpression. Additional studies are necessary to elucidate the mechanism by which PTP1B
may regulate IL-6 induced STAT3 phosphorylation.

Though JAK2 and TYK2 are known

substrates of PTP1B within the JAK-STAT signaling pathway, there is evidence suggesting
PTP1B may directly dephosphorylate STAT3 (Lund et al., 2005).

Taken together, the findings from the PTP1B KD and overexpression experiments suggest that
endogenous PTP1B is not a key regulator of IL-6-stimulated JAK-STAT signaling in mHypoE-N46
cells. Thus, enhanced IL-6 signaling likely does not underlie the improved metabolic effects of
PTP1B deficiency; however, given that increased PTP1B expression suppresses IL-6-induced
STAT3 activation in mHypoE-N46 cells, IL-6 signaling could be impaired when hypothalamic
PTP1B levels rise in the context of HFD-induced obesity or inflammation. Indeed, increased
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hypothalamic PTP1B expression has been demonstrated in mice with HFD-feeding or tumor
necrosis factor α (TNFα) administration (Zabolotny et al., 2008; White et al., 2009; Picardi et al.,
2010; Loh et al., 2011; Ito et al., 2012), and any effects on IL-6 signaling could be studied in these
models. Because different hypothalamic cell lines may exhibit different signaling capacities, the
preceding experiments could be repeated in different hypothalamic cultures (ex. GT1-7’s, other
mHypoE lines), or in vivo, to further explore PTP1B's potential role as a regulator of central IL-6
signaling.
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Figure 4.1 (A) Leptin induces JAK2 and STAT3 phosphorylation in mHypoE-N46 cells. mHypoEN46 cells were stimulated with vehicle or leptin (100 nM or 200 nM) for 1 or 10 minutes. Protein
was isolated and immunoblotted with anti-pJAK2, anti-JAK2, anti-pSTAT3, or anti-STAT3
antibodies. (B) IL-6 induces STAT3 phosphorylation independent of JAK2 or TYK2 activation.
mHypoE-N46 cells were unstimulated or treated with vehicle or IL-6 (1, 5, 10, or 20 ng/ml) for 15
minutes. Protein was isolated and immunoblotted with anti-pTYK2, anti-pJAK2, anti-JAK2, antipSTAT3, or anti-STAT3 antibodies. (C) IL-6 treatment does not affect PTP1B expression.
mHypoE-N46 cells were incubated with vehicle or 5ng/ml IL-6 for up to 2 hours. Protein was
isolated and immunoblotted for PTP1B.
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Figure 4.2 (A) PTP1B does not regulate IL-6-induced STAT3 activation in mHypoE-N46 cells.
mHypoE-N46 cells transduced with scramble or PTP1B shRNA and treated with vehicle or IL-6 (1
ng/ml) for up to 30 minutes. Protein was isolated and immunoblotted for pSTAT3, STAT3, and
PTP1B. (B) and (C) PTP1B overexpression suppresses IL-6-induced STAT3 phosphorylation.
mHypoE-N46 cells were transduced with PTP1B overexpression constructs (empty, WT) and
treated with vehicle or IL-6 (1 ng/ml) for 5 minutes. Protein was isolated and either
immunoblotted for pSTAT3, STAT3, or human PTP1B or immunoprecipitated with anti-JAK2 and
immunoblotted with anti-pTyr.
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CHAPTER 5: Conclusions and Future Directions

PTP1B is a ubiquitously expressed protein tyrosine phosphatase shown to centrally
regulate body weight and metabolism as demonstrated by a number of CNS-specific PTP1Bdeficient mouse models. Though improved leptin sensitivity is the putative mechanism by which
central PTP1B deletion confers protective body weight effects, whether or not PTP1B regulates
other leptin-independent pathways implicated in the control of energy balance remains unclear.
Here we studied the role of PTP1B and its interaction with leptin-dependent and leptinindependent signaling. In chapter 2, we demonstrated the extent to which the metabolic effects
of PTP1B deletion are mediated within leptin receptor-expressing cells. LepRb-specific PTP1B-/mice show an improved metabolic phenotype similar to that of whole body PTP1B-/- mice,
indicating that PTP1B in LepRb-expressing cells plays a major role in the central control of
energy balance and glucose homeostasis. Next in chapter 3, we showed that not only does
PTP1B within the hypothalamus contribute to the central regulation of energy balance, but that
extrahypothalamic PTP1B also plays a role, as the extent of the metabolic improvements of
hypothalamic PTP1B-/- mice were relatively modest when qualitatively compared to that of whole
brain or LepRb-specific PTP1B-/- mice.

Furthermore, we demonstrated that the metabolic

benefits of hypothalamic PTP1B deficiency are dependent upon functional leptin receptor
signaling, indicating that PTP1B's regulation of body weight and metabolism is mediated through
leptin signaling within the hypothalamus. Finally, in chapter 4, we explored whether PTP1B could
regulate IL-6 signaling, a non-leptin cytokine implicated in the central control of energy balance.
Using an immortalized mouse hypothalamic cell line, we demonstrated that IL-6-stimulated
STAT3 signaling does not appear to be regulated by endogenous PTP1B, though overexpression
of PTP1B suppresses STAT3 activation. Taken together, these data highlight the continued
importance of leptin as an adiposity signal that controls energy balance and confirm PTP1B’s role
as a negative regulator of central leptin signaling.
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Anatomic localization of PTP1B's metabolic effects
Through the use of genetic mouse models, we have narrowed down the anatomic and
cell-type specificity of PTP1B's metabolic effects. While whole body or whole brain PTP1Bdeficiency yields an improved, lean metabolic phenotype (Elchebly et al., 1999; Klaman et al.,
2000; Bence et al., 2006), peripheral loss of PTP1B does not affect energy balance (Delibegovic
et al., 2007, 2009; Owen et al., 2012; Grant et al., 2013), indicating that PTP1B's metabolic
contribution is localized to the CNS. POMC neuron-specific PTP1B knockouts demonstrate that
PTP1B within POMC neurons also contributes to regulation of energy balance, however,
compared to whole brain PTP1B knockouts, POMC neuron-specific PTP1B deficient mice show
relatively minor improvements in body weight on HFD and no measurable differences when fed a
chow diet (Banno et al., 2010). In chapter 2, we demonstrate that PTP1B deficiency within
LepRb-expressing neurons largely recapitulates the metabolic phenotype of HFD-fed whole body
PTP1B knockouts, and like whole brain PTP1B knockouts show decreased body weight even
when fed a chow diet (Tsou et al., 2012). Figure 3.7 in chapter 3 schematizes the deletion sites
of all CNS PTP1B-deficient models to date. In this diagram, one can see that POMC neurons
represent a small subset of LepRb-expressing neurons, let alone the whole brain. Because of
this relatively constrained central POMC expression, the weaker metabolic phenotype is
representative of limited central PTP1B deletion. The remaining PTP1B expression in neuron
populations excluding POMC neurons likely accounts for the milder phenotype. In chapter 3, we
generate a hypothalamic PTP1B-deficient mouse model. Given that the hypothalamus is a major
control center for energy homeostasis and hypothalamic LepRb deficiency results in a strong
obese phenotype (Ring and Zeltser, 2010), we were surprised to see that hypothalamic PTP1B
knockouts display a relatively modest lean phenotype compared to that of whole body, whole
brain, and LepRb-expressing cell-specific PTP1B-deficient models. Taken together, the findings
from these CNS PTP1B deficient models suggest that the majority of PTP1B's central metabolic
contribution is localized to LepRb-expressing neurons, and PTP1B’s metabolic effects are
localized to both hypothalamic and extrahypothalamic LepRb-neuron populations.
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Several extrahypothalamic LepRb sites have been shown to affect energy balance. For
example, hindbrain LepRb neurons are also required for normal energy balance (Hayes et al.,
2010), and there is evidence of PTP1B’s regulation of hindbrain leptin signaling (De Jonghe et al.,
2012). Furthermore, hippocampal LepRb have been implicated in control of food intake and foodrelated memory. Direct injection of leptin into the ventral hippocampus suppresses food intake in
rats and blocks expression of appetitive conditioned place preference (Kanoski et al., 2011);
fl/fl

however, cortex and hippocampal PTP1B-defiency (PTP1B -Emx1-Cre) does not result in any
metabolic phenotype (Fuentes et al., 2012 and unpublished data), suggesting enhanced
hippocampal leptin sensitivity may not appreciably affect total energy balance. LepRb is also
expressed in dopaminergic neurons of the midbrain ventral tegmental area (VTA) (Figlewicz et
al., 2003). Direct VTA leptin administration suppresses food intake, and knockdown of VTA
LepRb in rats results in increased sucrose preference and an increase in HFD intake, suggesting
VTA leptin plays a role in hedonic energy intake (Hommel et al., 2006). Could VTA PTP1B
expression modulate reward value associated with palatable food intake? Examining whether or
not PTP1B can also regulate energy balance in these LepRb-expressing regions would further
hone in on its exact CNS sites of action.

PTP1B and the central circuits regulating energy balance
The hypothalamus has long been regarded as a major CNS region controlling energy
balance. Hypothalamic lesion studies in the early-mid 20th century and Kennedy's proposed
endocrine feedback model have paved our understanding of the central control of energy
homeostasis (Brooks, 1948; Kennedy, 1951, 1953). With the discovery of central leptin signaling
and melanocortinergic pathways in the hypothalamus, a hypothalamus-centric model of energy
balance has developed wherein first order, leptin-sensing neurons in the arcuate nucleus detect
adiposity signals from the periphery and project directly to second order neurons as well as
indirectly to neurons (hypothalamic or extrahypothalamic) further downstream. Within this
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framework, PTP1B deletion (in LepRb-expressing cells for example) would sensitize leptin
signaling within first order neurons, resulting in greater inhibition of AgRP neurons and enhanced
activation of melanocortin neurons as well as downstream second order neurons involved in
catabolic effects on energy balance.

More recently, the limitations of the hypothalamus-centric model of central energy
homeostasis regulation have become apparent with its simplified unidirectional flow of
information. If circuits beginning at the level of the hypothalamus were the primary regulators of
energy balance, then we would have expected a more robust metabolic effect of hypothalamic
PTP1B deletion as sensitization at the start of the circuit would presumably enhance downstream
neuron activity. The relatively modest body weight improvements of deleting PTP1B in first order
hypothalamic neurons lend support for a more distributed model of CNS energy balance control
wherein first order neurons are located at different sites across the brain, and broad
interconnectivity between these sites (hypothalamus, midbrain, hindbrain) results in coordinated
processing of peripheral energy status signals (Grill and Hayes, 2012). Indeed, the CNS appears
to receive energy status input from the periphery via multiple sources (blood-borne signals to both
the hypothalamus and hindbrain, vagal afferents to hindbrain) and involves numerous
interconnected regions including the aforementioned extrahypothalamic LepRb-expressing sites
in addition to the hypothalamus. The enhanced hindbrain leptin sensitivity in POMC-PTP1B
deficient mice (De Jonghe et al., 2012) suggests PTP1B can regulate energy balance at the level
of peripheral input to the hindbrain NTS in addition to the arcuate nucleus of the hypothalamus.
Furthermore, the relatively robust metabolic improvements seen in LepRb-PTP1B-/- mice when
compared to the moderately improved body weight of Nkx2.1-PTP1B-/- mice suggest
anatomically distributed central PTP1B-deficiency can enhance CNS catabolic energy balance
processing.
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Accounting for early development
The findings from chapters 2 and 3, as well as past PTP1B-deficient mouse models,
demonstrate that genetic deletion of PTP1B results in an improved metabolic phenotype, but all
models described to date have early loss of PTP1B at embryonic stages, leaving open the
possibility that changes during development account for the metabolic benefits of PTP1B
deficiency rather than a direct loss of gene/protein function. Two questions come to mind: could
early PTP1B deficiency be changing developing feeding/metabolic circuits, resulting in the
observed phenotypes? Moreover, can one produce metabolic improvements if PTP1B is deleted
or inhibited in adults, once developmental programming has completed? Leptin deficiency has
been shown to profoundly affect the development of hypothalamic circuits; ob/ob mice display
permanent disruptions to arcuate-paraventricular nucleus projections which cannot be rescued in
adulthood (Bouret and Simerly, 2004; Bouret et al., 2004). Could early leptin sensitivity elicited
by PTP1B deletion enhance leptin’s trophic effects producing an overabundance of arcuate
neuronal projections? Gross brain morphology is normal in CNS PTP1B-deficient models, and no
changes were observed in α-melanocyte-stimulating hormone labeled projections to the PVN in
the brains of POMC-PTP1B-/- mice (Banno et al., 2010). Additional research is warranted to
further explore whether early loss of PTP1B can affect trophic signaling or possibly neuron
activity, leading to changes in CNS circuit development.

Whether or not adult PTP1B deficiency can bring about metabolic improvements is
currently unknown, though recent evidence supports this idea. Adult diet-induced obese rats with
third ventricle administration of PTP1B anti-sense oligonucleotides demonstrate decreased body
weight, adiposity, and food intake, and increased central leptin and insulin sensitivity compared to
rats treated with PTP1B sense oligonucleotides (Picardi et al., 2008).

Furthermore,

pharmacological inhibition of PTP1B in 20-week old, leptin-resistant rats enhances central leptininduced food intake suppression (Morrison et al., 2007). To further explore the metabolic effects
of adult PTP1B deficiency, our lab is currently using stereotaxic injections of AAV (adeno-
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associated virus) driving Cre expression into adult diet-induced obese PTP1B fl/fl mice. Using
this method, we can target PTP1B for deletion at any age and examine whether central loss of
PTP1B can rescue diet-induced weight gain in vivo after the fact. Animals will be compared to
age-matched control mice injected with AAV expressing GFP. Because this method is based on
stereotaxic coordinates, we can further explore the contribution of different hypothalamic and
extrahypothalamic nuclei at different developmental time points. Additionally, our lab is currently
exploring the use of inducible-Cre mouse lines (Feil et al., 2009) as another alternative method to
generate PTP1B mutants with tight temporal and spatial control.

Models of leptin resistance and the role of PTP1B in the pathogenesis of obesity
Whether leptin resistance is an underlying cause or consequence of obesity remains
unclear; however, cellular leptin resistance can increase susceptibility to obesity and likely
contributes to weight gain. Several mechanisms of cellular leptin resistance have been proposed,
including decreased leptin transport across the blood brain barrier and dysfunction of leptin
receptor signaling at the molecular/cellular level (Myers et al., 2012). Indeed, HFD-feeding has
been shown to diminish leptin transport and increase expression of SOCS-3 and PTP1B
(Bjørbaek et al., 1999; Levin et al., 2004; White et al., 2009; Lou et al., 2010). The mechanisms
by which over-nutrition provoke increased expression of leptin's negative regulators remains
unclear.

Increased food intake and associated adiposity leads to elevated circulating leptin

levels, and leptin has been shown to induce both SOCS-3 and PTP1B expression (Bjørbaek et
al., 1999; White et al., 2009). Therefore, increased feedback inhibition in this context may
promote leptin resistance. Alternatively, increased dietary fat increases circulating saturated fatty
acids which are known to activate hypothalamic inflammatory pathways implicated in disrupted
leptin signaling. For example, toll-like receptor 4 (TLR4) in the brain can be activated by longchain saturated fatty acids (Moraes et al., 2009), and activity of the downstream serine kinase
IKKβ/nuclear factor-κB (NF-κB) has been linked to leptin resistance via increased SOCS-3
expression (Zhang et al., 2008).

Furthermore, palmitate has been shown to induce PTP1B
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expression in skeletal muscle cells via activation of the IKKβ/NF-κB pathway, raising the
interesting possibility that a similar mechanism may occur in the brain (MohammadTaghvaei et
al., 2012). In addition to increased leptin levels and circulating fatty acids, long-term high-fat
feeding can lead to hyperglycemia. Little is known about the role of central PTP1B in neuronal
glucose sensing, although high-fructose feeding has been implicated in the development of
hypothalamic leptin resistance (Bursać et al., 2014) and has been shown to induce PTP1B
activity and expression within the liver (Li et al., 2010).

Although central PTP1B deletion can clearly sensitize leptin signaling resulting in a lean
metabolic phenotype, whether or not PTP1B actively plays a role in the development of obesity
pathology is less clear. One possible way to test this would be to generate mice with tissuespecific PTP1B overexpression (OE). We hypothesize that CNS-targeted PTP1B OE would yield
susceptibility to obesity and increased weight gain. To generate CNS site-specific PTP1B OE,
one could generate a line of transgenic mice with a floxed-stop cassette upstream of a wildtype
Ptpn1 transgene driven by a constitutive promoter. These stop-floxed PTP1B OE mice could
subsequently be crossed with LepRb-Cre or Nkx2.1-Cre mice to determine if PTP1B OE
exclusively within LepRb-expressing cells or the hypothalamus can produce an obese phenotype.
Overexpression of human PTP1B in muscle leads to impaired insulin signaling and whole body
insulin resistance in mice (Zabolotny et al., 2004); therefore PTP1B OE in LepRb-expressing cells
or the hypothalamus could potentially lead to site-specific leptin resistance. On the other hand,
while SOCS-3 OE in POMC neurons results in increased body weight and adiposity, SOCS-3 OE
in LepRb-expressing cells yields an unexpected lean phenotype (Reed et al., 2010). Careful
examination of PTP1B OE in different CNS sites will be necessary to determine whether it plays a
pathological role in leptin resistance and obesity.
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Confirmation of non-leptin pathway regulation
In chapter 3, we determined that the metabolic effects of hypothalamic PTP1B deficiency
require intact leptin signaling and discussed the possibility of two models of PTP1B’s central
regulation of energy balance: (a) PTP1B's metabolic role in the CNS is exclusively as a negative
regulator of leptin signaling, and the metabolic benefit of PTP1B deficiency is solely the result of
enhanced leptin sensitivity, or (b) PTP1B acts on multiple signaling pathways (e.g. insulin, nonleptin cytokines, growth factors etc.) including leptin, and the metabolic effects of PTP1B
deficiency are a combination of numerous sensitized pathways of which leptin is the major
contributor.

The latter model seems more likely given PTP1B’s known regulation of insulin

signaling and the evidence of enhanced hypothalamic insulin signaling and insulin-induced food
intake suppression with CNS PTP1B knockdown via anti-sense oligonucleotides (Picardi et al.,
2008). However, the insulin and leptin pathways have also been shown to have the potential for
significant crosstalk through PI3K activation, which has been implicated in pharmacological food
intake suppressive effects (Niswender and Schwartz, 2003; Niswender et al., 2003; Belgardt and
Brüning, 2010).

To further examine whether CNS PTP1B can regulate non-leptin signaling

pathways, we can begin by looking at whether PTP1B deficiency affects insulin-induced anorexia
–/–

or PI3K-activation. Insulin can be administered via third ventricle ICV into Nkx2.1-LepRb
–/–

–/–

Nkx2.1-PTP1B :LepRb

mice, and food intake and markers of insulin signaling can be
–/–

measured to see if Nkx2.1-PTP1B :LepRb
–/–

Nkx2.1-LepRb

and

–/–

mice display enhanced insulin sensitivity relative to

mice.

Furthermore, the PTP1B:LepRb double mutant studies from Chapter 3 can be repeated
using a pan-neuronal Cre line to examine whether or not total CNS PTP1B has leptin–/–

independent metabolic effects. Comparing Nkx2.1-PTP1B

mice to previous PTP1B-deficient

mice suggests that both hypothalamic and extrahypothalamic PTP1B contribute to its metabolic
effects. Repeating this study is not without its challenges however, as currently available pan-
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neuronal Cre lines each have their own disadvantages (e.g. Nestin-Cre and Synapsin-Cre) and
would require the generation of large animal cohorts with thorough controls (Harno et al., 2013).

We demonstrated in chapter 4 that endogenous PTP1B does not appear to regulate IL-6stimulated JAK-STAT signaling in mHypoE-N46 cells. Further study is required to map out which
janus kinase, if any, is responsible for STAT3 activation in mHypoE-N46 cells. Additionally, we
found that PTP1B overexpression suppresses IL-6-stimulated STAT3 activation in mHypoE-N46
cells. Given that increased hypothalamic PTP1B expression is associated with HFD-feeding and
TNFα administration (Zabolotny et al., 2008; White et al., 2009; Picardi et al., 2010; Ito et al.,
2012), hypothalamic IL-6 signaling could be further explored in both in vitro and in vivo models of
nutrient excess and/or increased inflammation. Interestingly, IL-6 has been shown to suppress
hypothalamic PTP1B expression (Chiarreotto-Ropelle et al., 2013), suggesting the possibility of
reciprocal regulation. Additional studies are required to determine exactly how hypothalamic
PTP1B can regulate IL-6 signaling, and vice versa.

PTP1B as a target for therapy: potential and challenges
Because of its role as a negative regulator of leptin and insulin signaling, PTP1B has
become an attractive target for potential pharmacological intervention in the treatment of obesity
and type 2 diabetes. A variety of PTP1B genetic mouse models, including the ones described in
this thesis, demonstrate that limiting PTP1B’s function could potentially lead to improved
metabolic outcomes.

While genetic deletion of Ptpn1 in mice produces profound metabolic

phenotypes, the metabolic benefits of pharmacological inhibition of PTP1B in humans are
unclear; however, findings from whole body, whole brain, LepRb-expressing cell-specific, and
hypothalamic PTP1B+/- mouse models suggest that body weight improvements can even be
conferred by partial loss of function (Klaman et al., 2000; Bence et al., 2006; Tsou et al., 2012).
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Thus, designing small molecules to inhibit PTP1B is a compelling approach with great potential
towards treating and preventing metabolic syndrome and its associated disorders.

Developing highly-specific drugs targeted against PTP1B is not without its challenges.
PTPs can regulate different pathways dependent upon tissue or cellular context. For example,
PTP1B has been demonstrated to regulate growth factor-activated pathways in which loss of
function could have severe, deleterious tumorigenic effects. PTP1B is a negative regulator of
epidermal growth factor receptor and platelet-derived growth factor receptor pathways (Flint et al.,
1997; Liu and Chernoff, 1997).

Interestingly, PTP1B can play either a tumor-suppressor or

tumorigenic role (Yip et al., 2010).

Loss of PTP1B in tumor-prone p53 mutants results in

decreased survivability and increased susceptibility to tumor formation (Dubé et al., 2005). In
contrast, in human cases of breast cancer, PTP1B protein levels are elevated (Wiener et al.,
1994), and loss of PTP1B in mice susceptible to mammary tumor growth led to delays in tumor
onset (Bentires-Alj and Neel, 2007; Julien et al., 2007). Therefore, safe and effective PTP1B
inhibitors require exquisite anatomic/cellular specificity in order to prevent potential tumorigenic
side effects while permitting the desired, beneficial metabolic outcomes.

Separate from its role in cancer, PTP1B also plays a role in non-metabolic CNS functions
which could yield potential side effects of drug action. PTP1B expression has been shown to
affect hippocampal dendritic spine morphology. Interestingly, hippocampus and cortex-specific
PTP1B-deficient mice show an enhancement in learning and memory tasks (Fuentes et al.,
2012), suggesting that PTP1B inhibition may prove fruitful outside of enhancing CNS leptin
signaling. Past reports demonstrate leptin and insulin having opposing effects on POMC neuron
excitability (Cowley et al., 2001; Choudhury et al., 2005; Plum et al., 2006; Williams et al., 2010);
PTP1B deficiency, therefore, could not only affect the sensitivity of intracellular signaling, but also
neuron activity. Future research is essential for clarifying the metabolic and non-metabolic CNS
effects of PTP1B in order to advance effective and safe therapeutic development.
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